U.S. patent application number 13/285880 was filed with the patent office on 2012-02-23 for analyte sensing biointerface.
This patent application is currently assigned to DexCom, Inc.. Invention is credited to James H. Brauker, Peter C. Simpson.
Application Number | 20120046534 13/285880 |
Document ID | / |
Family ID | 44910040 |
Filed Date | 2012-02-23 |
United States Patent
Application |
20120046534 |
Kind Code |
A1 |
Simpson; Peter C. ; et
al. |
February 23, 2012 |
ANALYTE SENSING BIOINTERFACE
Abstract
Disclosed herein is an analyte sensing biointerface that
comprises a sensing electrode incorporated within a non-conductive
matrix comprising a plurality of passageways extending through the
matrix to the sensing electrode. Also disclosed herein are methods
of manufacturing a sensing biointerface and methods of detecting an
analyte within tissue of a host using an analyte sensing
biointerface.
Inventors: |
Simpson; Peter C.;
(Encinitas, CA) ; Brauker; James H.; (Addison,
MI) |
Assignee: |
DexCom, Inc.
San Diego
CA
|
Family ID: |
44910040 |
Appl. No.: |
13/285880 |
Filed: |
October 31, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11404929 |
Apr 14, 2006 |
8060174 |
|
|
13285880 |
|
|
|
|
60671622 |
Apr 15, 2005 |
|
|
|
60683923 |
May 23, 2005 |
|
|
|
Current U.S.
Class: |
600/347 |
Current CPC
Class: |
A61B 5/1486 20130101;
C12Q 1/001 20130101; A61B 5/14865 20130101; A61B 5/0031 20130101;
A61B 5/14532 20130101; B33Y 80/00 20141201; C12Q 1/006
20130101 |
Class at
Publication: |
600/347 |
International
Class: |
A61B 5/1468 20060101
A61B005/1468 |
Claims
1. A glucose sensor configured for implantation in a host,
comprising: a biocompatible matrix comprising a scaffolding having
a porosity; a working electrode comprising an electrically
conductive material, wherein an electroactive surface of the
working electrode is distributed throughout the biocompatible
matrix; and electronics electrically coupled to the working
electrode, wherein, in use, the electronics are configured to
detect a current flowing through the working electrode or a voltage
of the working electrode, wherein the current or voltage is
indicative of a quantity of an analyte within the porosity.
2. The glucose sensor of claim 1, wherein the scaffolding comprises
an electrically non-conductive material.
3. The glucose sensor of claim 2, wherein the scaffolding further
comprises an electrically conductive material.
4. The glucose sensor of claim 1, wherein the scaffolding is
substantially planar.
5. The glucose sensor of claim 1, wherein the biocompatible matrix
comprises an enzyme.
6. The glucose sensor of claim 5, wherein the biocompatible matrix
further comprises a resistance domain disposed over the enzyme.
7. The glucose sensor of claim 5, wherein the biocompatible matrix
further comprises a bioactive agent.
8. A sensor for measuring glucose in a host, the sensor comprising:
a biointerface, the biointerface comprising a porous biointerface
material, wherein electroactive surfaces are distributed within at
least some pores in the biointerface, and wherein the electroactive
surfaces have a membrane coating disposed thereon; and electronics
electrically coupled to the sensor, such that, in use, the
electronics are configured to detect a current or a voltage
indicative of a quantity of glucose within the pores.
9. The sensor of claim 8, wherein the biointerface comprises an
electrically non-conductive material.
10. The sensor of claim 9, wherein the biointerface further
comprises an electrically conductive material.
11. The sensor of claim 8, wherein the biointerface is
substantially planar.
12. The sensor of claim 8, wherein the biointerface comprises an
enzyme.
13. The sensor of claim 12, wherein the biointerface further
comprises a resistance domain disposed over the enzyme.
14. The sensor of claim 8, wherein the biointerface further
comprises a bioactive agent.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 11/404,929, filed Apr. 14, 2006, which claims the benefit of
U.S. Provisional Application No. 60/671,622, filed Apr. 15, 2005,
and U.S. Provisional Application No. 60/683,923, filed May 23,
2005, each of which is incorporated herein by reference in its
entirety and each of which is hereby made a portion of this
specification.
FIELD OF THE INVENTION
[0002] The present invention relates to the field of biosensing.
More particularly, the present invention relates to analyte sensors
for implantation into a host.
BACKGROUND OF THE INVENTION
[0003] Biosensors are devices that can be used to detect the
presence or amount of analytes, such as biomolecules, in a
biological sample. Some biosensors are designed to detect analytes
in a living host. Such detection can advantageously be done through
the use of implantable biosensors, which are implanted
intravascularly or within tissue to detect the presence or amount
of analyte at the implantation location. One practical application
of implantable biosensors is implantable glucose sensors that
continuously monitor a patient's blood glucose level.
[0004] One type of implantable glucose sensor utilizes glucose
oxidase that catalyzes the reaction between glucose and oxygen to
produce gluconic acid and hydrogen peroxide. The hydrogen peroxide
can be detected by measuring the electrochemical oxidation of the
hydrogen peroxide at an appropriate electrode, such as a platinum
electrode. The current generated by this oxidation can be related
to the amount of hydrogen peroxide in the vicinity of the
electrode, and hence, the amount of glucose in the vicinity of the
sensor. In some glucose sensors, the electrode is coated with an
analyte membrane system. The analyte membrane system may contain
the glucose oxidase enzyme as well as one or more polymeric
membranes that control the diffusion of glucose or block or limit
certain undesired species from reaching the electrode, such as is
described further in U.S. application Ser. No. 10/153,356, filed on
May 22, 2002, which is incorporated herein by reference in its
entirety.
[0005] One difficulty encountered with implantable biosensors, such
as implantable glucose sensors, is that many of these devices tend
to lose their function with time after implantation. While not
being bound by any particular theory, this decrease in function can
at least partially be attributed to the host's foreign body
response (FBR) to the implant. Typical FBR response to an
implantable biosensor is illustrated in FIG. 1. FBR is a local
inflammatory response that results in the formation of a barrier
cell layer 40 around the surface of the implant 47. This layer
generally consists of macrophages and foreign body giant cells 41.
An intermediate layer 42, consisting of fibroblasts 43 and a
fibrous matrix 44, typically form over the barrier cell layer 40.
Finally, an outer layer 46 consisting of loose connective granular
tissue and new blood vessels 45 forms over the intermediate layer.
The barrier cell layer 40 can have the adverse effect of blocking
transport of the analyte to the analyte sensor 47. Furthermore,
lack of vascularization in the intermediate 42 and barrier cell 40
layers decreases analyte availability to the sensor. Thus, once the
FBR acts to induce the above-described tissue growth around the
implanted biosensor, sensing ability decreases.
SUMMARY OF THE INVENTION
[0006] Devices and methods are needed that address the FBR's
negative effects on biosensing. The devices and methods of the
preferred embodiments address these negative effects, and offer
other benefits and advantages, as described herein.
[0007] Accordingly, in a first aspect, an implantable analyte
sensor is provided, comprising an electrically non-conductive
biocompatible matrix comprising a plurality of passageways
extending from openings in an exterior surface of the matrix into
an interior portion of the matrix; a working electrode comprising
an electrically conductive material, wherein an electroactive
surface of the working electrode is within the matrix; and
electronics electrically coupled to the working electrode, the
electronics configured to detect a current flowing through the
working electrode or a voltage of the working electrode, wherein
the current or voltage is indicative of a quantity of an analyte
within the passageways.
[0008] In an embodiment of the first aspect, the implantable sensor
comprises a membrane coating surfaces of at least some of the
passageways in the interior portion of the matrix, the membrane
comprising a component that affects a rate of diffusion of the
analyte through the membrane.
[0009] In an embodiment of the first aspect, the implantable sensor
comprises a membrane coating surfaces of at least some of the
passageways in the interior portion of the matrix, the membrane
comprising a component that is capable of reacting with the analyte
to produce a species that is capable of electrochemically reacting
at a surface of the working electrode.
[0010] In an embodiment of the first aspect, the implantable sensor
comprises a reference electrode disposed within the matrix, wherein
an electroactive surface of the reference electrode is within the
matrix, and wherein at least a portion of the matrix electrically
insulates the reference electrode from the working electrode.
[0011] In an embodiment of the first aspect, the implantable sensor
comprises a reference electrode disposed on an exterior surface of
the matrix, wherein at least a portion of the matrix electrically
insulates the reference electrode from the working electrode.
[0012] In an embodiment of the first aspect, the implantable sensor
comprises a counter electrode disposed within the matrix, wherein
an electroactive surface of the counter electrode is within the
matrix, and wherein at least a portion of the matrix electrically
insulates the counter electrode from the working electrode.
[0013] In an embodiment of the first aspect, the implantable sensor
comprises a counter electrode disposed on an exterior surface of
the matrix, wherein at least a portion of the matrix electrically
insulates the counter electrode from the working electrode.
[0014] In an embodiment of the first aspect, the matrix is a
substantially solid material and the passageways comprise pores
within the substantially solid material. The matrix can be a mesh
of fibers. The fibers can comprise an electrically non-conductive
material or an electrically conductive material. The fibers can
further comprise a membrane coating the fibers.
[0015] In an embodiment of the first aspect, the working electrode
has a membrane coating disposed thereon.
[0016] In a second aspect, a sensor is provided for measuring an
analyte in a host, the sensor comprising a biointerface comprising
a porous biocompatible matrix, wherein electroactive surfaces are
distributed within at least some pores in the biointerface.
[0017] In an embodiment of the second aspect, the electroactive
surfaces have a membrane coating disposed thereon.
[0018] In an embodiment of the second aspect, the porous
biocompatible matrix is configured to support tissue ingrowth and
comprises a plurality of interconnected cavities and a solid
portion, and wherein a substantial number of the interconnected
cavities are greater than or equal to about 20 microns in at least
one dimension.
[0019] In an embodiment of the second aspect, the porous
biocompatible matrix comprises a length of greater than one cavity
in each of three dimensions substantially throughout the
matrix.
[0020] In an embodiment of the second aspect, the cavities and a
plurality of cavity interconnections are formed in a plurality of
layers, wherein each layer has different cavity dimensions.
[0021] In an embodiment of the second aspect, the porous
biocompatible matrix is configured to promote vascularization and
interfere with barrier cell layer formation within the matrix,
whereby the biocompatible matrix is suitable for long-term analyte
transport in vivo.
[0022] In an embodiment of the second aspect, the porous
biocompatible matrix comprises a plurality of fibers.
[0023] In an embodiment of the second aspect, the plurality of
fibers are selected from the group consisting of woven fibers and
non-woven fibers.
[0024] In an embodiment of the second aspect, at least a portion of
the plurality of fibers comprise an electrode core.
[0025] In an embodiment of the second aspect, the fibers comprising
an electrode core comprise a membrane surrounding the electrode
core.
[0026] In an embodiment of the second aspect, the electroactive
surfaces comprise an electroactive surface of at least one working
electrode.
[0027] In an embodiment of the second aspect, the electroactive
surfaces further comprise an electroactive surface of at least one
reference electrode.
[0028] In an embodiment of the second aspect, the sensor further
comprises sensor electronics operably connected to the
electroactive surfaces.
[0029] In an embodiment of the second aspect, the sensor is
configured to measure glucose.
[0030] In a third aspect, a sensor for measuring an analyte in a
host is provided, the sensor comprising an analyte sensing
mechanism disposed within a porous biocompatible matrix.
[0031] In an embodiment of the third aspect, dimensions of the
porous biocompatible matrix comprising the sensing mechanism are
less than about 1000 microns.
[0032] In an embodiment of the third aspect, the porous
biocompatible matrix and the sensing mechanism are configured to
resist barrier cell layer formation.
[0033] In an embodiment of the third aspect, the sensing mechanism
comprises a working electrode.
[0034] In an embodiment of the third aspect, the working electrode
is a wire electrode.
[0035] In an embodiment of the third aspect, the working electrode
is a substantially planar electrode.
[0036] In an embodiment of the third aspect, the sensing mechanism
further comprises an enzyme domain disposed over the working
electrode.
[0037] In an embodiment of the third aspect, the sensing mechanism
further comprises an electrode domain disposed between the enzyme
domain in the working electrode.
[0038] In an embodiment of the third aspect, the sensing mechanism
further comprises a resistance domain disposed over the enzyme
domain.
[0039] In an embodiment of the third aspect, the sensing mechanism
further comprises a bioprotective domain disposed over the enzyme
domain.
[0040] In an embodiment of the third aspect, the sensing mechanism
further comprises a resistance domain disposed between the enzyme
domain and the bioprotective domain.
[0041] In a fourth aspect, a method of detecting an analyte within
tissue of a host is provided, comprising implanting an analyte
sensor according to the first aspect within the tissue; allowing
tissue to grow within at least a portion of some of the
passageways; and detecting current flowing through the working
electrode or a voltage of the working electrode, thereby detecting
the quantity of an analyte within the passageways.
[0042] In an embodiment of the fourth aspect, allowing tissue to
grow within at least a portion of some of the passageways comprises
formation of one or more host tissue materials within the
passageways, the host tissue materials selected from the group
consisting of a fibrous matrix, blood vessels, fibroblasts,
connective granular tissue, macrophages, and foreign body giant
cells.
[0043] In a fifth aspect, a method of manufacturing an analyte
sensor according to the first aspect is provided, comprising
forming a first layer of an electrically non-conductive material;
depositing a layer of an electrically conductive material on the
first layer of the electrically non-conductive material; depositing
a second layer of electrically non-conductive material onto the
layer of electrically conductive material; and etching the
deposited layers to form interconnected pores in the layers, at
least some of the pores extending from an exterior surface of the
electrically non-conductive material to the electrically conductive
material.
[0044] In an embodiment of the fifth aspect, at least one of the
forming and depositing steps comprises dip coating.
[0045] In an embodiment of the fifth aspect, at least one of the
forming and depositing steps comprises vapor deposition.
[0046] In an embodiment of the fifth aspect, at least one of the
forming and depositing steps comprises lamination.
[0047] In an embodiment of the fifth aspect, at least one of the
forming and depositing steps comprises spin coating.
[0048] In an embodiment of the fifth aspect, the method further
comprises coating the pores' interior surfaces with an analyte
membrane system, the analyte membrane system comprising at least
one of a component that affects the analyte's rate of diffusion
through the analyte membrane system and a component that reacts
with the analyte to produce a species that electrochemically reacts
at the surface of the electrically conductive material.
[0049] In an embodiment of the fifth aspect, coating comprises dip
coating.
[0050] In an embodiment of the fifth aspect, coating comprises
vapor deposition.
[0051] In an embodiment of the fifth aspect, coating comprises spin
coating.
[0052] In a sixth aspect, a method of manufacturing an analyte
sensor according to the first aspect is provided, comprising
depositing a first layer of an electrically non-conductive material
onto a substrate; depositing a first layer of an electrically
conductive material onto the first layer of the electrically
non-conductive material; depositing a second layer of electrically
non-conductive material onto the first layer of electrically
conductive material; depositing a second layer of electrically
conductive material onto the second layer of electrically
non-conductive material; depositing a third layer of electrically
non-conductive material onto the second layer of electrically
conductive material; depositing a third layer of electrically
conductive material onto the third layer of electrically
non-conductive material; depositing a fourth layer of electrically
non-conductive material onto the third layer of electrically
conductive material; and etching the deposited layers to form pores
in the layers, at least some of the pores extending from an
exterior surface of the electrically non-conductive material and
contacting all three layers of electrically conductive
material.
[0053] In an embodiment of the sixth aspect, at least one of the
depositing steps comprises dip coating.
[0054] In an embodiment of the sixth aspect, at least one of the
depositing steps comprises vapor deposition.
[0055] In an embodiment of the sixth aspect, at least one of the
depositing steps comprises lamination.
[0056] In an embodiment of the sixth aspect, the method further
comprises coating the pores' interior surfaces with an analyte
membrane system, the analyte membrane system comprising at least
one of a component that affects the analyte's rate of diffusion
through the analyte membrane system and a component that reacts
with the analyte to produce a species that electrochemically reacts
at the surface of the electrically conductive material.
[0057] In an embodiment of the sixth aspect, coating comprises dip
coating.
[0058] In an embodiment of the sixth aspect, coating comprises
vapor deposition.
[0059] In a seventh aspect a method of manufacturing an analyte
sensor according to the first aspect is provided, comprising
depositing a first layer of an electrically conductive material
onto a substrate; depositing a first layer of an electrically
non-conductive material onto the first layer of electrically
conductive material; depositing a second layer of electrically
conductive material onto the first layer of electrically
non-conductive material; depositing a second layer of electrically
non-conductive material onto the second layer of electrically
conductive material; depositing a third layer of electrically
conductive material onto the second layer of electrically
non-conductive material; and etching the deposited layers to form
pores in the layers, at least some of the pores extending from an
exterior surface of either the first or third layers of
electrically conductive material and contacting the second layer of
electrically conductive material and the other first or third
layers of electrically conductive material.
[0060] In an embodiment of the seventh aspect, at least one of the
depositing steps comprises dip coating.
[0061] In an embodiment of the seventh aspect, at least one of the
depositing steps comprises vapor deposition.
[0062] In an embodiment of the seventh aspect, at least one of the
depositing steps comprises lamination.
[0063] In an embodiment of the seventh aspect, at least one of the
depositing steps comprises spin coating.
[0064] In an embodiment of the seventh aspect, the method further
comprises coating the pores' interior surfaces with an analyte
membrane system, the analyte membrane system comprising at least
one of a component that affects the analyte's rate of diffusion
through the analyte membrane system and a component that reacts
with the analyte to produce a species that electrochemically reacts
at the surface of the electrically conductive material.
[0065] In an embodiment of the seventh aspect, coating comprises
dip coating.
[0066] In an embodiment of the seventh aspect, coating comprises
vapor deposition.
BRIEF DESCRIPTION OF THE DRAWINGS
[0067] FIG. 1 depicts foreign body response near the surface of an
implanted biosensor.
[0068] FIG. 2 depicts foreign body response near the surface of an
implanted biosensor in the presence of a cell-disruptive
biointerface.
[0069] FIG. 3 depicts cell disruptive material comprising a solid
matrix with cavities therein.
[0070] FIG. 4 depicts an implantable analyte sensor comprising a
membrane system and a cell-disruptive biointerface.
[0071] FIG. 5A depicts a side schematic view of a sensing
biointerface that incorporates electrodes within fibers.
[0072] FIG. 5B depicts a cross-sectional view through line 5B-5B of
FIG. 5A showing some fibers that form the biointerface in the
embodiment of FIG. 5A.
[0073] FIG. 5C depicts a cross-sectional expanded view of one fiber
shown in FIG. 5B, showing an electrode surrounded by a membrane
system.
[0074] FIG. 6A depicts a schematic surface view of a sensing
cell-disruptive biointerface that comprises pores and incorporates
electrodes within the biointerface.
[0075] FIG. 6B depicts a cross-sectional view through line 6B-6B of
FIG. 6A, showing the through porosity of the biointerface.
[0076] FIG. 6C depicts a cross-sectional expanded view of a portion
of the cross-sectional view of FIG. 6B showing the membrane system
within the pores of the biointerface.
[0077] FIG. 7 depicts a flowchart of a process for manufacturing a
sensing biointerface.
[0078] FIGS. 8A and 8B depict cross-sectional views of a sensing
cell-disruptive biointerface comprising a mesh structure that
incorporates electrodes as part of the biointerface.
[0079] FIG. 9A depicts a schematic surface view of a sensing
biointerface that includes a biointerface matrix surrounding a
sensing mechanism.
[0080] FIG. 9B depicts a wire-like analyte sensing mechanism in one
exemplary embodiment, which can be incorporated into the
biointerface matrix to form the sensing biointerface.
[0081] FIG. 9C depicts a schematic cross-sectional view of a
sensing biointerface in one embodiment, including a single wire
sensor incorporated into a cylindrical shaped biointerface
matrix.
[0082] FIG. 9D is a schematic cross-sectional view of a sensing
biointerface in another embodiment wherein the sensing biointerface
includes a plurality of wire electrodes.
[0083] FIG. 9E is a schematic cross-sectional view of a sensing
biointerface in yet another embodiment wherein the sensing
biointerface comprises a spiral wire electrode.
[0084] FIG. 9F is a schematic cross-sectional view of a sensing
biointerface in yet another embodiment wherein the sensing
biointerface comprises a wire electrode in a tortuous path within
the biointerface matrix.
[0085] FIG. 9G is a schematic cross-sectional view of a sensing
biointerface in yet another embodiment, wherein the sensing
biointerface comprises a wire electrode, a biointerface matrix, and
a sensor body.
[0086] FIG. 10 is a flow chart that illustrates a process of
dispensing a fibrous biointerface matrix onto a sensing
mechanism.
[0087] FIG. 11 is a flow chart that illustrates a process of
molding a biointerface matrix onto a sensing mechanism.
[0088] FIG. 12 is a flow chart that illustrates an alternative
process of molding a biointerface matrix onto a sensing
mechanism.
[0089] FIG. 13 is a flow chart that illustrates a process of
wrapping a sensing mechanism with a biointerface membrane.
[0090] FIG. 14 is a flow chart that illustrates a process of
inserting a sensing mechanism into a biointerface matrix.
[0091] FIG. 15 depicts a block diagram of the sensor electronics in
one embodiment.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
[0092] Described herein are structures for use in implantable
analyte sensors. The term "analyte" as used herein is a broad term,
and is to be given its ordinary and customary meaning to a person
of ordinary skill in the art (and is not to be limited to a special
or customized meaning), and refers without limitation to a
substance or chemical constituent in a biological fluid (e.g.,
blood, urine, extracellular fluid) that is intended to be analyzed.
In one embodiment, the analyte is blood glucose. The term
"detection" of an analyte as used herein is a broad term, and is to
be given its ordinary and customary meaning to a person of ordinary
skill in the art (and is not to be limited to a special or
customized meaning), and refers without limitation to detecting the
presence of an analyte and/or detecting the amount of an analyte
present. In one embodiment, detection of an analyte provides a
measure of the concentration of the analyte in a biological
fluid.
[0093] One method of addressing foreign body response to implanted
biosensors is illustrated in FIG. 2, which depicts FBR in the
presence of a biointerface. The biointerface is constructed of a
barrier cell disruptive material 49 that is incorporated on the
surface of the biosensor 50. The material 49 disrupts the
continuity of cells 41 so that an impermeable barrier cell layer
does not form. All of the FBR cells and materials may be present,
such as foreign body giant cells 41, fibroblasts 43, fibrous matrix
44, blood vessels 45, and connective granular tissue; however,
orderly formation of the barrier cell, intermediate, and outer
layers is inhibited. Thus, transport of the analyte to the sensor
is not blocked and blood vessels can grow closer to the biosensor
50.
[0094] The biointerface comprising barrier cell disruptive material
49 may be constructed from non-woven fibers, such as illustrated in
FIG. 2. Alternatively, the biointerface may be woven fiber mesh.
FIG. 3 depicts another barrier cell disruptive layer 66. The
barrier cell disruptive layer 66 consists of a solid material 62 in
which cavities 64 are formed as depicted in FIG. 3. In order to
ensure that the analyte can pass from the tissue side of the
barrier cell disruptive layer 66 to the sensor side, it is
advantageous that at least some cavities 64 extend uninterrupted
from the tissue side to the sensor side.
[0095] FIG. 4 depicts an implantable analyte sensor configuration
that makes use of a barrier cell disruptive biointerface 33. The
sensor typically comprises a working electrode 21, a reference
electrode 20, and an optional counter electrode 22. These
electrodes may be insulated from each other by insulative layers 28
and further be housed in housing 10. The reference electrode 20
provides a stable-voltage electrode relative to which the voltage
of the working electrode 21 can be controlled or detected. The
optional counter electrode 22 draws the current flowing through the
working electrode 20 so that the current through the reference
electrode 20 is kept at a minimum, thus maintaining its voltage
stability. The end surfaces of all three electrodes are
advantageously coated with membrane system 32, which may comprise a
layer of glucose oxidase enzyme. The membrane system 32 may then be
coated with the barrier cell disruptive biointerface 33.
[0096] Biointerfaces for promoting tissue in-growth adjacent to a
biosensor are described in more detail in U.S. Pat. No. 6,702,857,
which is incorporated herein by reference in its entirety.
The Sensing Biointerface
[0097] Some embodiments of the present invention comprise combining
the sensor electrodes and membrane system into the cell-disruptive
biointerface (for example, a porous biointerface material). Thus,
the cell-disruptive biointerface becomes a sensing biointerface.
This combination may be embodied by providing an electrically
non-conductive biocompatible matrix within which at least the
working electrode can be incorporated, which together function as
the biointerface. However, in some alternative embodiments, the
biocompatible matrix comprises electrically conductive materials,
for example, that function as a working electrode, without a
requirement for a non-conductive material within the matrix.
Passageways (e.g., interconnected pores or cavities) can be formed
within the matrix or designed into the matrix to provide openings
for FBR tissue in-growth near to the working electrode and provide
analyte access to the working electrode.
[0098] The term "electrically non-conductive" material as used
herein is a broad term, and is to be given its ordinary and
customary meaning to a person of ordinary skill in the art (and is
not to be limited to a special or customized meaning), and refers
without limitation to material that allows no current or little
current to flow under the voltages typically applied to the
electrodes in biosensors. Non-limiting examples of electrically
non-conductive materials include insulators such as plastics and
other non-conductive polymers, non-conductive inorganics such as
oxides, and semi-conductors exhibiting low conductivity such as
un-doped silicon.
[0099] The term "electrically conductive" material as used herein
is a broad term, and is to be given its ordinary and customary
meaning to a person of ordinary skill in the art (and is not to be
limited to a special or customized meaning), and refers without
limitation to material through which readily detectable current
flows under the voltages typically applied to the electrodes in
biosensors. Non-limiting examples of electrically conductive
material include metallic conductors, conductive polymers, and
semi-conductors with appreciable conductivity.
[0100] Thus, some embodiments provide a porous biointerface, also
referred to as a biointerface matrix, comprising a biocompatible
matrix material wherein electroactive surfaces, with or without a
membrane system coating, are distributed within at least some pores
in the biointerface. In one embodiment, the sensing mechanism,
being within the biointerface, includes a morphology substantially
similar, complementary, or integral with the morphology of the cell
disruptive biointerface, thereby enabling manipulation of the
foreign body response to the sensing mechanism in a manner
substantially similar to that of a porous biointerface material
(e.g., cell-disruptive biointerface). While not wishing to be bound
by theory, it is believed that by providing a sensing mechanism
integrated throughout the biointerface, the cellular mechanisms of
the foreign body response will not substantially attack or attempt
to block the sensing mechanism as a foreign body as happens with
conventional analyte sensors. A few exemplary embodiments are
provided herein, however one skilled in the art will appreciate the
variety of systems and methods that can be implemented in order to
form the sensing biointerface described herein.
[0101] The biocompatible matrix, also referred to as biointerface
matrix, can comprise a variety of porous structures. In one
embodiment, the biocompatible matrix comprises a plurality of woven
or non-woven fibers, one example of which is described with
reference to FIGS. 5A to 5C. In another embodiment, the
biocompatible matrix comprises a solid structure with
interconnected pores or cavities formed therein, one example of
which is described with reference to FIGS. 6A to 6C. In another
example, the biocompatible matrix comprises a scaffolding defined
by uniform or non-uniform mesh, wire, or fiber layers, formed with
a through-porosity, one example of which is described with
reference to FIGS. 8A and 8B.
[0102] In some embodiments, the interconnected cavities (also
referred to as pores or passageways) are dimensioned such that
fibrous matrix, blood vessels, fibroblasts, connective granular
tissue, macrophages, and/or foreign body giant cells can migrate
through or grow therein. In some embodiments, the interconnected
cavities can be defined by one dimension (for example, shortest,
average, or longest) of the cavity. In some embodiments, the
dimensions can be defined by measuring techniques known in the art
of porous materials (for example, bubble point test). It should be
noted, that the term "nominal pore size" in the context of the
biocompatible matrix in certain embodiments is derived from methods
of analysis common to the membrane trade, such as the ability of
the membrane to filter particles of a particular size, or the
resistance of the membrane to the flow of fluids. It is noted,
however that the term "nominal pore size" may not actually indicate
the size or shape of the cavities, which in reality may have some
degree of variability. Accordingly, in some embodiments, the term
"nominal pore size" is a manufacturer's convention used to identify
a particular membrane of a particular commercial source which can
have a certain bubble point. One example of a bubble point
measurement is described in Pharmaceutical Technology May 1983 pp.
36 to 42, which is incorporated herein by reference in its
entirety.
[0103] In some embodiments, a substantial number of the cavities
defined using any of the methods described above, are greater than
or equal to about 20 microns in one dimension. In some other
embodiments, a substantial number of the cavities are greater than
or equal to about 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160,
180, 200, 240, 280, 320, 360, 400, 500, 600, 700 microns in one
dimension.
[0104] In some embodiments, a substantial number of the cavities,
defined using any of the methods described above, are less than or
equal to about 1000 microns in one dimension. In other embodiments,
a substantial number of the cavities are less than or equal to
about 900, 800, 700, 600, 500, 400, 360, 320, 280, 240, 200, 180,
160, 140, 120, 100 microns in one dimension.
[0105] In one alternative embodiment, wherein a substantial number
of cavities are greater than or equal to about 20 microns in one
dimension, there can be additional cavities that are less than or
equal to about 20 microns in their shortest dimension interspersed
therein. In another alternative embodiment, wherein a substantial
number of cavities are greater than or equal to about 20 microns in
one dimension, cavity dimensions can be gradually increased or
decreased progressively through the layer, including some cavities
that are less than or equal to about 20 microns in one
dimension.
[0106] In some embodiments, the biocompatible matrix includes
non-woven materials, woven materials, or other such materials, such
that a porous structure is formed from the cavities between the
fibers. In these embodiments, for example, the fibers are formed by
structural elements that provide the three-dimensional
conformation. Therefore in these embodiments, the biocompatible
matrix may be defined by a fiber size of between about 1 and 100
microns in all but the longest dimension and a sufficient number of
cavities of a size and structure to allow inflammatory cells (for
example, macrophages) to completely enter therein through the
apertures that define the cavities.
[0107] In some alternative embodiments, a bioactive agent is
incorporated into the above described biocompatible matrix, which
then diffuses out into the environment adjacent to the sensing
region in order to modify the tissue response of the host to the
device, for example, such as is described in U.S. Publication No.
US-2005-0031689-A1. Additionally or alternately, a bioactive agent
can be administered locally at the exit-site or implantation-site.
Suitable bioactive agents are those that modify the host's tissue
response to the sensor, for example anti-inflammatory agents,
anti-infective agents, anesthetics, inflammatory agents, growth
factors, immunosuppressive agents, antiplatelet agents,
anti-coagulants, anti-proliferates, ACE inhibitors, cytotoxic
agents, anti-barrier cell compounds, vascularization-inducing
compounds, anti-sense molecules, or mixtures thereof, such as are
described in more detail in co-pending U.S. Patent Publication No.
US-2005-0031689-A1.
[0108] In embodiments wherein the biocompatible matrix is designed
to enhance short-term (e.g., from about 1 to about 30 days)
lifetime or performance of the sensor, a suitable bioactive agent
can be chosen to ensure that tissue ingrowth does not substantially
occur within the cavities of the biocompatible matrix. For example,
by providing a tissue modifying bioactive agent, such as an
anti-inflammatory agent (for example, Dexamethasone), substantial
tissue ingrowth can be inhibited, at least in the short term, in
order to maintain sufficient glucose transport through the pores of
the biocompatible matrix to maintain a stable sensitivity.
[0109] In embodiments wherein the biocompatible matrix is designed
to enhance long-term (e.g., from about a day to about a year or
more) lifetime or performance of the sensor, a suitable bioactive
agent, such as a vascularization-inducing compound or anti-barrier
cell compound, can be chosen to encourage tissue ingrowth without
barrier cell formation.
[0110] The architectures of the first and second domains may
support vascularized tissue growth in or around the sensing
biointerface, interfere with and resist barrier cell layer
formation, and allow the transport of analytes through the porous
biocompatible matrix to the sensing mechanism. However, certain
outside influences, for example, faulty surgical techniques, acute
or chronic movement of the implant, or other surgery-, patient-,
and/or implantation site-related conditions, can create acute
and/or chronic inflammation at the implant site. When this occurs,
the sensing biointerface architecture alone may not be sufficient
to overcome the acute and/or chronic inflammation. Accordingly, in
some embodiments, the membrane architecture can benefit from
additional mechanisms that aid in reducing this acute and/or
chronic inflammation that can produce a barrier cell layer and/or a
fibrotic capsule surrounding the implant, resulting in compromised
solute transport through the membrane.
[0111] In general, the inflammatory response to biomaterial
implants can be divided into two phases. The first phase consists
of mobilization of mast cells and then infiltration of
predominantly polymorphonuclear (PMN) cells. This phase is termed
the acute inflammatory phase. Over the course of days to weeks,
chronic cell types that comprise the second phase of inflammation
replace the PMNs. Macrophage and lymphocyte cells predominate
during this phase. While not wishing to be bound by any particular
theory, it is believed that short-term stimulation of
vascularization, or short-term inhibition of scar formation or
barrier cell layer formation, provides protection from scar tissue
formation, thereby providing a stable platform for sustained
maintenance of the altered foreign body response.
[0112] Accordingly, bioactive intervention can modify the foreign
body response in the early weeks of foreign body capsule formation,
thereby fundamentally altering the long-term behavior of the
foreign body capsule. Additionally, it is believed that the sensing
biointerfaces of the preferred embodiments can advantageously
benefit from bioactive intervention to overcome sensitivity of the
membrane to implant procedure, motion of the implant, or other
factors, which are known to otherwise cause inflammation, scar
formation, and hinder device function in vivo.
[0113] In general, bioactive agents that are believed to modify
tissue response include anti-inflammatory agents, anti-infective
agents, anesthetics, inflammatory agents, growth factors,
angiogenic (growth) factors, adjuvants, wound factors, resorbable
device components, immunosuppressive agents, antiplatelet agents,
anticoagulants, ACE inhibitors, cytotoxic agents, anti-barrier cell
compounds, vascularization compounds, anti-sense molecules, and the
like. In some embodiments, preferred bioactive agents include S1P
(Sphingosine-1-phosphate), Monobutyrin, Cyclosporin A,
Anti-thrombospondin-2, Rapamycin (and its derivatives), and
Dexamethasone. However, other bioactive agents, biological
materials (for example, proteins), or even non-bioactive substances
can be preferred for incorporation into the membranes of preferred
embodiments.
[0114] Bioactive agents suitable for use in the preferred
embodiments are loosely organized into two groups: anti-barrier
cell agents and vascularization agents. These designations reflect
functions that are believed to provide short-term solute transport
through the sensing biointerface, and additionally extend the life
of a healthy vascular bed and hence solute transport through the
sensing biointerface long term in vivo. However, not all bioactive
agents can be clearly categorized into one or other of the above
groups; rather, bioactive agents generally comprise one or more
varying mechanisms for modifying tissue response and can be
generally categorized into one or both of the above-cited
categories.
[0115] Anti-Barrier Cell Agents
[0116] Generally, anti-barrier cell agents include compounds
exhibiting affects on macrophages and foreign body giant cells
(FBGCs). It is believed that anti-barrier cell agents prevent
closure of the barrier to solute transport presented by macrophages
and FBGCs at the device-tissue interface during FBC maturation.
[0117] Anti-barrier cell agents generally include mechanisms that
inhibit foreign body giant cells and/or occlusive cell layers. For
example, Super Oxide Dismutase (SOD) Mimetic, which utilizes a
manganese catalytic center within a porphyrin like molecule to
mimic native SOD and effectively remove superoxide for long
periods, thereby inhibiting FBGC formation at the surfaces of
biomaterials in vivo, may be incorporated into a sensing
biointerface of a preferred embodiment.
[0118] Anti-barrier cell agents can include anti-inflammatory
and/or immunosuppressive mechanisms that affect the wound healing
process, for example, healing of the wound created by the incision
into which an implantable device is inserted. Cyclosporine, which
stimulates very high levels of neovascularization around
biomaterials, can be incorporated into a sensing biointerface of a
preferred embodiment [see U.S. Pat. No. 5,569,462 to Martinson et
al., which is incorporated herein by reference in its entirety.]
Alternatively, Dexamethasone, which abates the intensity of the FBC
response at the tissue-device interface, can be incorporated into a
sensing biointerface of a preferred embodiment. Alternatively,
Rapamycin, which is a potent specific inhibitor of some macrophage
inflammatory functions, can be incorporated into a sensing
biointerface of a preferred embodiment.
[0119] Other suitable medicaments, pharmaceutical compositions,
therapeutic agents, or other desirable substances can be
incorporated into the membranes of preferred embodiments,
including, but not limited to, anti-inflammatory agents,
anti-infective agents, and anesthetics.
[0120] Generally, anti-inflammatory agents reduce acute and/or
chronic inflammation adjacent to the implant, in order to decrease
the formation of a FBC capsule to reduce or prevent barrier cell
layer formation. Suitable anti-inflammatory agents include but are
not limited to, for example, nonsteroidal anti-inflammatory drugs
(NSAIDs) such as acetaminophen, aminosalicylic acid, aspirin,
celecoxib, choline magnesium trisalicylate, diclofenac potassium,
diclofenac sodium, diflunisal, etodolac, fenoprofen, flurbiprofen,
ibuprofen, indomethacin, interleukin (IL)-10, IL-6 mutein,
anti-IL-6 iNOS inhibitors (for example, L-NAME or L-NMDA),
Interferon, ketoprofen, ketorolac, leflunomide, melenamic acid,
mycophenolic acid, mizoribine, nabumetone, naproxen, naproxen
sodium, oxaprozin, piroxicam, rofecoxib, salsalate, sulindac, and
tolmetin; and corticosteroids such as cortisone, hydrocortisone,
methylprednisolone, prednisone, prednisolone, betamethesone,
beclomethasone dipropionate, budesonide, dexamethasone sodium
phosphate, flunisolide, fluticasone propionate, paclitaxel,
tacrolimus, tranilast, triamcinolone acetonide, betamethasone,
fluocinolone, fluocinonide, betamethasone dipropionate,
betamethasone valerate, desonide, desoximetasone, fluocinolone,
triamcinolone, triamcinolone acetonide, clobetasol propionate, and
dexamethasone.
[0121] Generally, immunosuppressive and/or immunomodulatory agents
interfere directly with several key mechanisms necessary for
involvement of different cellular elements in the inflammatory
response. Suitable immunosuppressive and/or immunomodulatory agents
include anti-proliferative, cell-cycle inhibitors, (for example,
paclitaxel, cytochalasin D, infiximab), taxol, actinomycin,
mitomycin, thospromote VEGF, estradiols, NO donors, QP-2,
tacrolimus, tranilast, actinomycin, everolimus, methothrexate,
mycophenolic acid, angiopeptin, vincristing, mitomycine, statins, C
MYC antisense, sirolimus (and analogs), RestenASE,
2-chloro-deoxyadenosine, PCNA Ribozyme, batimstat, prolyl
hydroxylase inhibitors, PPAR.gamma. ligands (for example
troglitazone, rosiglitazone, pioglitazone), halofuginone,
C-proteinase inhibitors, probucol, BCP671, EPC antibodies,
catchins, glycating agents, endothelin inhibitors (for example,
Ambrisentan, Tesosentan, Bosentan), Statins (for example,
Cerivasttin), E. coli heat-labile enterotoxin, and advanced
coatings.
[0122] Generally, anti-infective agents are substances capable of
acting against infection by inhibiting the spread of an infectious
agent or by killing the infectious agent outright, which can serve
to reduce immuno-response without inflammatory response at the
implant site. Anti-infective agents include, but are not limited
to, anthelmintics (mebendazole), antibiotics including
aminoclycosides (gentamicin, neomycin, tobramycin), antifungal
antibiotics (amphotericin b, fluconazole, griseofulvin,
itraconazole, ketoconazole, nystatin, micatin, tolnaftate),
cephalosporins (cefaclor, cefazolin, cefotaxime, ceftazidime,
ceftriaxone, cefuroxime, cephalexin), beta-lactam antibiotics
(cefotetan, meropenem), chloramphenicol, macrolides (azithromycin,
clarithromycin, erythromycin), penicillins (penicillin G sodium
salt, amoxicillin, ampicillin, dicloxacillin, nafcillin,
piperacillin, ticarcillin), tetracyclines (doxycycline,
minocycline, tetracycline), bacitracin; clindamycin; colistimethate
sodium; polymyxin b sulfate; vancomycin; antivirals including
acyclovir, amantadine, didanosine, efavirenz, foscarnet,
ganciclovir, indinavir, lamivudine, nelfinavir, ritonavir,
saquinavir, silver, stavudine, valacyclovir, valganciclovir,
zidovudine; quinolones (ciprofloxacin, levofloxacin); sulfonamides
(sulfadiazine, sulfisoxazole); sulfones (dapsone); furazolidone;
metronidazole; pentamidine; sulfanilamidum crystallinum;
gatifloxacin; and sulfamethoxazole/trimethoprim.
[0123] Vascularization Agents
[0124] Generally, vascularization agents include substances with
direct or indirect angiogenic properties. In some cases,
vascularization agents may additionally affect formation of barrier
cells in vivo. By indirect angiogenesis, it is meant that the
angiogenesis can be mediated through inflammatory or immune
stimulatory pathways. It is not fully known how agents that induce
local vascularization indirectly inhibit barrier-cell formation;
however it is believed that some barrier-cell effects can result
indirectly from the effects of vascularization agents.
[0125] Vascularization agents include mechanisms that promote
neovascularization and accelerate wound healing around the membrane
and/or minimize periods of ischemia by increasing vascularization
close to the tissue-device interface. Sphingosine-1-Phosphate
(S1P), which is a phospholipid possessing potent angiogenic
activity, is incorporated into a sensing biointerface of a
preferred embodiment. Monobutyrin, which is a potent vasodilator
and angiogenic lipid product of adipocytes, is incorporated into a
sensing biointerface of a preferred embodiment. In another
embodiment, an anti-sense molecule (for example, thrombospondin-2
anti-sense), which increases vascularization, is incorporated into
a sensing biointerface.
[0126] Vascularization agents can include mechanisms that promote
inflammation, which is believed to cause accelerated
neovascularization and wound healing in vivo. In one embodiment, a
xenogenic carrier, for example, bovine collagen, which by its
foreign nature invokes an immune response, stimulates
neovascularization, and is incorporated into a sensing biointerface
of the preferred embodiments. In another embodiment,
Lipopolysaccharide, which is a potent immunostimulant, is
incorporated into a sensing biointerface. In another embodiment, a
protein, for example, a bone morphogenetic protein (BMP), which is
known to modulate bone healing in tissue, is incorporated into a
sensing biointerface of a preferred embodiment.
[0127] Generally, angiogenic agents are substances capable of
stimulating neovascularization, which can accelerate and sustain
the development of a vascularized tissue bed at the tissue-device
interface. Angiogenic agents include, but are not limited to, Basic
Fibroblast Growth Factor (bFGF), (also known as Heparin Binding
Growth Factor-II and Fibroblast Growth Factor II), Acidic
Fibroblast Growth Factor (aFGF), (also known as Heparin Binding
Growth Factor-I and Fibroblast Growth Factor-I), Vascular
Endothelial Growth Factor (VEGF), Platelet Derived Endothelial Cell
Growth Factor BB (PDEGF-BB), Angiopoietin-1, Transforming Growth
Factor Beta (TGF-Beta), Transforming Growth Factor Alpha
(TGF-Alpha), Hepatocyte Growth Factor, Tumor Necrosis Factor-Alpha
(TNF-Alpha), Placental Growth Factor (PLGF), Angiogenin,
Interleukin-8 (IL-8), Hypoxia Inducible Factor-I (HIF-1),
Angiotensin-Converting Enzyme (ACE) Inhibitor Quinaprilat,
Angiotropin, Thrombospondin, Peptide KGHK, Low Oxygen Tension,
Lactic Acid, Insulin, Copper Sulphate, Estradiol, prostaglandins,
cox inhibitors, endothelial cell binding agents (for example,
decorin or vimentin), glenipin, hydrogen peroxide, nicotine, and
Growth Hormone.
[0128] Generally, pro-inflammatory agents are substances capable of
stimulating an immune response in host tissue, which can accelerate
or sustain formation of a mature vascularized tissue bed. For
example, pro-inflammatory agents are generally irritants or other
substances that induce chronic inflammation and chronic granular
response at the wound-site. While not wishing to be bound by
theory, it is believed that formation of high tissue granulation
induces formation of blood vessels, which supply an adequate or
rich supply of analytes to the device-tissue interface.
Pro-inflammatory agents include, but are not limited to, xenogenic
carriers, Lipopolysaccharides, S. aureus peptidoglycan, and
proteins.
[0129] Other substances that can be incorporated into membranes of
preferred embodiments include various pharmacological agents,
excipients, and other substances well known in the art of
pharmaceutical formulations.
[0130] Bioactive Agent Delivery Systems and Methods
[0131] There are a variety of systems and methods by which the
bioactive agent may be incorporated into the sensing biointerface
of the preferred embodiments. In some embodiments, the bioactive
agent is incorporated at the time of manufacture of the sensing
biointerface. For example, the bioactive agent can be blended into
any of the membrane and/or biointerface materials prior to curing,
or subsequent to their manufacture, for example, by coating,
imbibing, solvent-casting, or sorption of the bioactive agent into
the sensing biointerface. Although the bioactive agent is
preferably incorporated into the sensing biointerface, in some
embodiments the bioactive agent can be administered concurrently
with, prior to, or after implantation of the device systemically,
for example, by oral administration, or locally, for example, by
subcutaneous injection near the implantation site. In some
embodiments, a combination of bioactive agent(s) incorporated in
the sensing biointerface and bioactive agent(s) administration
locally and/or systemically is used.
[0132] In embodiments wherein the sensing biointerface of the
preferred embodiments include a bioactive agent, the bioactive
agent can be incorporated into numerous aspects of the device,
including electrically conductive or non-conductive portions,
insulator or membrane materials, and/or other materials that form
the biointerface. In some embodiments, the bioactive agent is
sprinkled or sprayed on the surface of the device, for example,
using known deposition techniques.
[0133] The bioactive agent can include a carrier matrix, wherein
the matrix includes one or more of collagen, a particulate matrix,
a resorbable or non-resorbable matrix, a controlled-release matrix,
and/or a gel. In some embodiments, the carrier matrix includes a
reservoir, wherein a bioactive agent is encapsulated within a
microcapsule. The carrier matrix can include a system in which a
bioactive agent is physically entrapped within a polymer network.
In some embodiments, the bioactive agent is cross-linked with
certain materials of the sensing biointerface, while in others the
bioactive agent is sorbed into the materials, for example, by
adsorption, absorption, or imbibing. The bioactive agent can be
deposited in or on the sensing biointerface, for example, by
coating, filling, or solvent casting. In certain embodiments, ionic
and nonionic surfactants, detergents, micelles, emulsifiers,
demulsifiers, stabilizers, aqueous and oleaginous carriers,
solvents, preservatives, antioxidants, or buffering agents are used
to incorporate the bioactive agent into the sensing biointerface.
The bioactive agent can be incorporated into a polymer using
techniques such as described above, and the polymer can be used to
form the sensing biointerface, coatings on the sensing
biointerface, portions of the sensing biointerface, and/or a
portion of an implantable device.
[0134] The sensing biointerface can be manufactured using
techniques such as described here and/or as are known in the art.
The bioactive agent can be sorbed into the sensing biointerface,
for example, by soaking the sensing biointerface for a length of
time (for example, from about an hour or less to about a week or
more, preferably from about 4, 8, 12, 16, or 20 hours to about 1,
2, 3, 4, 5, or 7 days).
[0135] The bioactive agent can be blended into uncured polymer
prior to forming the sensing biointerface (or a portion thereof).
The sensing biointerface (or a portion thereof) is then cured and
the bioactive agent thereby cross-linked and/or encapsulated within
the polymer that forms the sensing biointerface (or a portion
thereof). For example, Monobutyrin was covalently bonded to a
silicone matrix in such a manner that is slowly cleavable under in
vivo conditions. The alcohol groups of Monobutyrin react with a
silanol group, resulting in a C--O--Si bond. This bond is known to
be susceptible to hydrolysis, and is therefore cleaved to yield the
original alcohol and silanol. Thus, the Monobutyrin is released
from the silicone matrix according to the rate of hydrolysis. Other
bioactive agents, such as Dexamethasone, comprise alcohol groups
and can be bound to a silicone matrix in a similar manner.
[0136] In yet another embodiment, microspheres are used to
encapsulate the bioactive agent. The microspheres can be formed of
biodegradable polymers, most preferably synthetic polymers or
natural polymers such as proteins and polysaccharides. In this
context, the term polymer is used to refer to both to synthetic
polymers and proteins. U.S. Pat. No. 6,281,015, which is
incorporated herein by reference in its entirety, discloses some
systems and methods that can be used in conjunction with the
preferred embodiments. In general, bioactive agents can be
incorporated in (1) the polymer matrix forming the microspheres,
(2) microparticle(s) surrounded by the polymer which forms the
microspheres, (3) a polymer core within a protein microsphere, (4)
a polymer coating around a polymer microsphere, (5) mixed in with
microspheres aggregated into a larger form, or (6) a combination
thereof. Bioactive agents can be incorporated as particulates or by
co-dissolving the factors with the polymer. Stabilizers can be
incorporated by addition of the stabilizers to the factor solution
prior to formation of the microspheres.
[0137] The bioactive agent can be incorporated into a hydrogel and
coated or otherwise deposited in or on the sensing biointerface.
Some hydrogels suitable for use in the preferred embodiments
include cross-linked, hydrophilic, three-dimensional polymer
networks that are highly permeable to the bioactive agent and are
triggered to release the bioactive agent based upon exposure to a
stimulus.
[0138] The bioactive agent can be incorporated into the sensing
biointerface by solvent casting, wherein a solution including
dissolved bioactive agent is disposed on the surface of the sensing
biointerface, after which the solvent is removed to form a coating
on the membrane surface.
[0139] In yet another embodiment, the interconnected cavities of
the sensing biointerface are filled with the bioactive agent.
Preferably, a bioactive agent, with or without a carrier matrix,
fills the cavities of the membrane, depending on the loading and
release properties desired, which are discussed in more detail
below.
[0140] Short-term release of the bioactive agent in the preferred
embodiments generally refers to release over a period of from about
1 day or less to about 2, 3, 4, 5, 6, or 7 days, 2 or 3 weeks, 1
month, or more. More preferably, the short-term release of the
bioactive agent occurs over from about 14, 15, 16, 17, or 18 days
up to about 19, 20, or 21 days.
[0141] Some devices, such as implantable analyte measuring-devices,
drug delivery devices, and cell transplantation devices, that
require transport of solutes across the device-tissue interface for
proper function, tend to lose their function after the first few
days following implantation. At least one reason for this loss of
function is the lack of direct contact with circulating fluid for
appropriate analyte transport to the device. Therefore, in some
embodiments, short-term release of certain bioactive agents, for
example vascularization agents, can increase the circulating fluid
to the device for an extended period of time.
[0142] Additionally, it is believed that short-term release of the
bioactive agent can have a positive effect of the functionality of
porous sensing biointerface during the initial tissue ingrowth
period prior to formation of a capillary bed. For example, when a
device requiring analyte transport across its device-tissue
interface is implanted, a "sleep period" can occur which begins as
early as the first day after implantation and extends as far as one
month after implantation. However shorter sleep periods are more
common. During this sleep period, extensive ingrowth of tissue into
the porous structure causes the inflammatory cells responsible for
facilitating wound healing to proliferate within the local
environment of the wound region. Because these cells are respiring,
they consume some or all of the analyte (e.g., glucose) and oxygen
that is within the wound environment, which has been shown to block
adequate flow of analytes to the implantable device. Accordingly in
some embodiments, it is believed that short-term release of certain
bioactive agents, for example vascularization agents, can aid in
providing adequate vascularization to substantially overcome the
effects of the sleep period, and thereby allow sufficient analytes
to pass through to the implantable device.
[0143] Additionally, it is believed that short-term release of the
bioactive agent can have an enhanced effect on neovascularization
at the tissue-device interface. Although neovascularization alone
is generally not sufficient to provide sufficient analyte transport
at the device-tissue interface, in combination with other
mechanisms, enhanced neovascularization can result in enhanced
transport of analytes from the host to the implanted device.
Therefore in some embodiments, short-term release of certain
bioactive agents, for example angiogenic agents, can have a
positive effect on neovascularization and thereby enhance transport
of analytes at the device-tissue interface.
[0144] Additionally, it is believed that short-term release of the
bioactive agent may be sufficient to reduce or prevent barrier cell
layer formation. Formation of a cohesive monolayer of closely
opposed cells, e.g., macrophages and foreign body giant cells,
interfere with the transport of analytes across the tissue-device
interface, also known as a barrier cell layer, and are large
contributors to poor device performance. See U.S. Pat. No.
6,702,857, which is incorporated herein by reference in its
entirety. Therefore in some embodiments, it is believed that
short-term release of certain bioactive agents, for example,
anti-barrier cell agents, can aid in preventing barrier cell layer
formation.
[0145] Additionally, it is believed that short-term release of the
bioactive agent may be sufficient to prevent negative effects of
acute inflammation caused, for example, by surgical trauma,
micro-motion, or macro-motion of the device in the soft tissue.
Short-term release of anti-inflammatory agents may be sufficient to
rescue a sensing biointerface from the negative effects associated
with such acute inflammation, rendering adequate analyte
transport.
[0146] Long-term release of the bioactive agent in the preferred
embodiments generally occurs over a period of from about 1 month to
about 2 years or more, preferably from at least about 2 months to
at least about 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23
months, and more preferably from at least about 3 months to at
least about 4, 5, 6, 7, 8, 9, 10, 11, or 12 months.
[0147] Long-term glucose-measuring device experiments demonstrate
that many biointerface materials experience a distinct and
continual decline in sensitivity, for example, reduced analyte
transport, beginning at three months after implantation in some
cases. It is believed that this decline in analyte transport can be
a result of barrier cell layer formation, cellular growth at the
membrane, and/or thickening of the fibrous elements of the foreign
body capsule. Other contributing factors can include chronic
inflammation, which is believed to be due to micro-motion or
macro-motion of the device; delamination of the sensing
biointerface, which is believed to be due to cellular ingrowth
within and under the sensing biointerface; compression of the
sensing biointerface due to increasing compression of the foreign
body capsule around the device; and distortion of the sensing
biointerface, which is believed to be a result of a combination of
compression and cellular ingrowth, for example.
[0148] Accordingly, long-term release of certain bioactive agents
can modulate the foreign body response sufficiently to prevent
long-term thickening of the foreign body capsule, reduce or prevent
barrier cell layer formation, reduce or prevent chronic
inflammation, reduce or prevent extensive cellular ingrowth, and/or
reduce or prevent compression of the foreign body capsule on the
sensing biointerface.
[0149] Loading of Bioactive Agents
[0150] The amount of loading of the bioactive agent into the
sensing biointerface can depend upon several factors. For example,
the bioactive agent dosage and duration can vary with the intended
use of the sensing biointerface, for example, cell transplantation,
analyte measuring-device, and the like; differences among patients
in the effective dose of bioactive agent; location and methods of
loading the bioactive agent; and release rates associated with
bioactive agents and optionally their carrier matrix. Therefore,
one skilled in the art will appreciate the variability in the
levels of loading the bioactive agent, for the reasons described
above.
[0151] In some embodiments, wherein the bioactive agent is
incorporated into the sensing biointerface without a carrier
matrix, the preferred level of loading of the bioactive agent into
the sensing biointerface can vary depending upon the nature of the
bioactive agent. The level of loading of the bioactive agent is
preferably sufficiently high such that a biological effect is
observed. Above this threshold, bioactive agent can be loaded into
the sensing biointerface so as to imbibe up to 100% of the solid
portions, cover all accessible surfaces of the membrane, and/or
fill up to 100% of the accessible cavity space. Typically, the
level of loading (based on the weight of bioactive agent(s),
sensing biointerface, and other substances present) is from about 1
ppm or less to about 1000 ppm or more, preferably from about 2, 3,
4, or 5 ppm up to about 10, 25, 50, 75, 100, 200, 300, 400, 500,
600, 700, 800, or 900 ppm. In certain embodiments, the level of
loading can be 1 wt. % or less up to about 50 wt. % or more,
preferably from about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 wt. %
up to about 25, 30, 35, 40, or 45 wt. %.
[0152] When the bioactive agent is incorporated into the sensing
biointerface with a carrier matrix, such as a gel, the gel
concentration can be optimized, for example, loaded with one or
more test loadings of the bioactive agent. It is generally
preferred that the gel contain from about 0.1 or less to about 50
wt. % or more of the bioactive agent(s), preferably from about 0.2,
0.3, 0.4, 0.5, 0.6, 0.7, 0.8, or 0.9 wt. % to about 6, 7, 8, 9, 10,
15, 20, 25, 30, 35, 40, or 45 wt. % or more bioactive agent(s),
more preferably from about 1, 2, or 3 wt. % to about 4 or 5 wt. %
of the bioactive agent(s). Substances that are not bioactive can
also be incorporated into the matrix.
[0153] Referring now to microencapsulated bioactive agents, the
release of the agents from these polymeric systems generally occurs
by two different mechanisms. The bioactive agent can be released by
diffusion through aqueous filled channels generated in the dosage
form by the dissolution of the agent or by voids created by the
removal of the polymer solvent or a pore forming agent during the
original micro-encapsulation. Alternatively, release can be
enhanced due to the degradation of the polymer. With time, the
polymer erodes and generates increased porosity and microstructure
within the device. This creates additional pathways for release of
the bioactive agent.
Sensing Biointerface Based Sensors
[0154] Generally, the sensor electrodes comprise at least one
working electrode incorporated into the biocompatible matrix. In
some embodiments, at least one reference electrode is incorporated
into the biocompatible matrix; however it is possible that the
reference electrode exists at a location other than within the
biocompatible matrix. In some embodiments, a counter electrode is
incorporated into the biocompatible matrix, however it is possible
that the counter electrode exists at a location other than within
the biocompatible matrix or does not exist at all.
[0155] FIG. 5A is a schematic surface view of a sensing
biointerface in one embodiment, wherein a biocompatible matrix is
formed from a plurality of fibers formed into a porous biointerface
structure 50. In this embodiment, the plurality of fibers that form
the biocompatible matrix 50 include at least some fibers formed
from an electrode material surrounded by a membrane system (also
referred to as an electrode-membrane fiber), which fibers are
configured to measure an analyte. In some embodiments, all of the
fibers of the biocompatible matrix are electrode-membrane fibers,
however in some alternative embodiments some portion of the fibers
that form the biocompatible matrix may be formed from insulating
materials or other non-conductive materials. Furthermore, in some
embodiments, fibers may be present that comprise an electrode
material that is exposed directly to the cavities between the
fibers without a membrane coating.
[0156] In the illustrated embodiment, the fibers are formed into a
non-woven fiber matrix, which is generally manufactured by
interlocking or bonding a plurality of fibers together. In some
alternative embodiments, the sensing biointerface can be formed
into a woven fiber matrix, which is generally manufactured by
weaving the fibers together. In some other alternative embodiments,
the sensing biointerface can be formed into a uniform or
non-uniform scaffolding, which is generally manufactured by bonding
an array of fibers together.
[0157] FIG. 5B is a cross-sectional view taken along line 5B-5B of
FIG. 5A, showing a plurality of electrode-membrane fibers 52 in
cross-section. In this embodiment, at least one working electrode
54 may be provided, wherein the working electrode 54 may be
surrounded by a multi-layer membrane system. In some embodiments,
the biocompatible matrix comprises a plurality of working,
reference, and/or counter electrodes, some or all of which may be
electrode-membrane fibers. However, not all embodiments include a
membrane system and/or electrode cores in some or all of the
fibers. Generally, the biocompatible matrix comprises between about
1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% to about 20, 30, 40, 50, 60, 70,
80, 90, or 100% of its fibers with an electrode core. Although FIG.
5B depicts an electrode-membrane fiber 52 near the periphery of the
fiber bundle, those of skill in the art will appreciate that such
electrode-membrane fibers may be located at any location within the
fiber bundle. For example, in some embodiments, electrode-membrane
fibers are located at a central position within the fiber
bundle.
[0158] FIG. 5C is an expanded view of one of the electrode-membrane
fibers 52 of FIG. 5B in cross-section, showing the membrane system
surrounding the fiber. The electrode-membrane fiber comprises a
core formed from an electrode material (e.g. working electrode 54).
In some embodiments, the electrode core comprises a wire or other
bulk metal formed into an appropriate size and shape.
Alternatively, the electrode core comprises a substrate onto which
the electrode material is deposited utilizing techniques known in
the art, for example, thin or thick film techniques. Preferably,
the electrode core comprises any suitable conductive material, for
example gold, silver, platinum, palladium, iridium, lead,
conducting polymers, or other non-metal electrodes such as graphite
or other carbon materials.
[0159] In general, the membrane system functions to control the
flux of a biological fluid therethrough and/or to protect sensitive
regions of the sensor from contamination by the biological fluid,
for example. Some conventional electrochemical enzyme-based analyte
sensors generally include a membrane system that controls the flux
of the analyte being measured, protects the electrodes from
contamination of the biological fluid, and/or provides an enzyme
that catalyzes the reaction of the analyte with a co-factor, for
example. See, e.g., co-pending U.S. patent application Ser. No.
10/838,912, filed May 3, 2004 entitled "IMPLANTABLE ANALYTE
SENSOR," U.S. patent application Ser. No. 11/077,715, filed Mar.
10, 2005 and entitled "TRANSCUTANEOUS ANALYTE SENSOR," and U.S.
patent application Ser. No. 11/360,819, filed Feb. 22, 2006
entitled "ANALYTE SENSOR," all of which are incorporated herein by
reference in their entirety.
[0160] The membrane systems of the preferred embodiments can
include any membrane configuration suitable for use with any
analyte sensor (such as described in more detail above). In
general, the membrane systems of the preferred embodiments include
a plurality of domains, all or some of which can be adhered to or
deposited on the analyte sensor as is appreciated by one skilled in
the art. In one embodiment, the membrane system generally provides
one or more of the following functions: 1) protection of the
exposed electrode surface from the biological environment, 2)
diffusion resistance (limitation) of the analyte, 3) a catalyst for
enabling an enzymatic reaction, 4) limitation or blocking of
interfering species, and 5) hydrophilicity at the electrochemically
reactive surfaces of the sensor interface, such as described in
more detail in co-pending U.S. patent application Ser. No.
10/838,912, filed May 3, 2004 entitled "IMPLANTABLE ANALYTE
SENSOR," U.S. patent application Ser. No. 11/077,715, filed Mar.
10, 2005 and entitled "TRANSCUTANEOUS ANALYTE SENSOR," and U.S.
patent application Ser. No. 11/360,250, filed Feb. 22, 2006, and
entitled "ANALYTE SENSOR", all of which are incorporated herein by
reference in their entirety. Accordingly, in one embodiment, the
membrane system include a plurality of domains or layers, for
example, an electrode (or electrolyte) domain 56, an interference
domain 57, an enzyme domain 58, and a resistance domain 59, and may
include additional domains, such as a bioprotective domain, a cell
impermeable domain, and/or an oxygen domain (not shown), such as
described in more detail in the above-cited co-pending U.S. Patent
Applications and below. However, it is understood that a membrane
system modified for other sensors, for example, by including fewer
or additional domains is within the scope of the preferred
embodiments.
[0161] In one example of a glucose sensor, one or more working
electrode-membrane fibers, one or more reference electrode fibers,
and one or more counter electrode fibers are formed into a
non-woven biocompatible matrix. The matrix is connected to
appropriate electronics (e.g., as shown in FIG. 10) and implanted
in a host. The connection between the electrodes and electronics
may be accomplished by electrically coupling each electrode within
each electrode-containing fiber with the electronics. For example,
in one embodiment, each working electrode 54 is electrically
coupled, such as by spot welding or other suitable technique, to a
single electrical contact, which is then coupled to the sensing
electronics. Over time, as the host's tissue grows in and through
the passageways of the biocompatible matrix, a mature bed of
vascularized tissue will form, enabling long term measurement of
the analyte in vivo. While not wishing to be bound by theory, it is
believed that the host response to a sensing biointerface of the
preferred embodiments will enable long term measurement of an
analyte due to tissue ingrowth into and through the passageways of
the porous biocompatible matrix. It is noted, however, that
measurement of the analyte prior to tissue ingrowth is also
possible and/or with the incorporation of bioactive agents can be
manipulated for a variety of lengths and/or time periods.
[0162] FIG. 6A depicts a schematic surface view of a sensing
cell-disruptive biointerface 90 that incorporates electrodes as
part of the biointerface in an alternative embodiment. In this
embodiment, openings 115 are shown on the surface of the
biointerface that provide access to pores within the through-porous
biointerface. Openings 115 may be formed on all sides of the
biointerface. In some embodiments, the openings and pores are
formed into the biointerface by drilling or etching (e.g., laser
drilling or photolithography), which is described in more detail
below.
[0163] FIG. 6B depicts a cross-sectional view through line 6B-6B of
FIG. 6A showing the through-porosity of the biointerface. In this
embodiment, the biointerface 90 includes a sheet having multiple
layers, for example, alternating non-conductive and conductive
layers. Conductive layer 100 is the working electrode, conductive
layer 102 is the counter electrode, and conductive layer 104 is the
reference electrode. The working electrode 100 is separated from
the counter electrode 102 and reference electrode 104 by
non-conductive layers 106 and 108. The counter electrode 102 and
reference electrode 104 are separated from tissue surrounding the
implant by non-conductive layers 110 and 112. Because the
electrodes 100, 102, and 104 are incorporated within the
biointerface 90 rather than being adjacent to it as depicted in
FIG. 4, the biointerface 90 may contact body tissue on both sides.
In other words, both non-conductive layers 110 and 112 will be in
contact with surrounding body tissue.
[0164] Non-limiting examples of material that may be used for
non-conductive layers 106, 108, 110, and 112 include
polytetrafluoroethylene, polyethylene-co-tetrafluoroethylene,
polyurethanes, block copolymers, and silicone.
[0165] In some embodiments, the working electrode 100 and the
counter electrode 102 are constructed from platinum. The counter
electrode 102 advantageously has low impedance. Thus, in some
embodiments, the counter electrode 102 has an exposed surface area
(e.g., surface area exposed to the inside surface of pores 114) at
least several fold greater than the exposed surface area of the
working electrode 100. In some embodiments, the reference electrode
104 is a silver/silver chloride reference electrode (e.g., it
consists of a layer of silver and an adjacent layer of silver
chloride).
[0166] The sensing biointerface 90 advantageously has the form of a
thin membrane. In one embodiment, the biointerface 90 is
approximately 300 microns thick.
[0167] A plurality of pores 114 extend throughout biointerface 90.
The size of pores 114 are such that tissue may grow into the pores
during the body's FBR response. However, the size and distribution
of the pores 114 are sufficient to disrupt the continuity of cells
growing within the pores 114, thus preventing formation of a
barrier cell layer on the interior surfaces of the pores 114. The
porous structure throughout sensing biointerface 90 creates a
structure similar to the biointerface depicted in FIG. 3, with the
exception that electrodes 100, 102, and 104 are part of the porous
structure. It will be appreciated that tissue growth can occur in
pores that have an opening 115 on the exterior surface of the
biointerface 90. Tissue in-growth may also occur in pores that do
not have an opening on the exterior surface of biointerface 90 but
that intersect other pores that do have openings on the exterior
surface of biointerface 90.
[0168] It will be appreciated that the pores 114 within
biointerface 90 may make any angle relative to the surfaces of the
biointerface 90 and relative to each other and that they may follow
a non-straight path within the biointerface 90. It will also be
appreciated that the pores 114 may have non-uniform size. In one
embodiment, a substantial number of the pores 114 are not less than
20 microns in the shortest dimension and not more than 1000 microns
in the longest dimension. In one embodiment, a substantial number
of the pores are not less than 25 microns in the shortest dimension
and not more than 500 microns in the longest dimension.
[0169] As depicted in FIGS. 6B and C, where a pore 114 extends
through one of the conductive layers 100, 102, or 104, an interface
point 116 is formed between the inside surface of the pore 114 and
the electrode 100, 102, or 104. Thus, electrochemical reactions
between agents in the pores 114 are possible at interface points
116. Interface points 130 between a pore 114 and working electrode
100 provide a point where analyte sensing can occur. In some
embodiments, a plurality of interface points 130 are provided that
enable analyte sensing in locations substantially distributed
throughout the biointerface. Alternatively, only one or a few
interface points could be provided that enable analyte sensing in
locations substantially distributed throughout the biointerface. In
general, it is advantageous to have a substantial number of pores
114 that extend from one of the surfaces of the biointerface 90 to
at least the working electrode 100.
[0170] FIG. 6C depicts a cross-sectional expanded view of a portion
of the cross-sectional view of FIG. 6B showing the membrane system
within the pores of the biointerface in one embodiment. In some
implantable analyte sensors, analyte detection using a structure
such as sensing biointerface 90 may be used without a membrane
system. In other sensors, such as a glucose sensor, it is
advantageous to include a membrane system. Membrane system 137 may
be coated on the interior surfaces of pores 114. The coating 137
will then provide an interface between the interior of pores 114
and interface points 130, 133, and 135. Thus, for example, in a
glucose sensor, glucose supplied within pores 114 by in-grown
vasculature will diffuse through membrane system 137, contact
glucose oxidase enzyme situated at the interface between the
membrane system 137 and the working electrode, where it will be
oxidized producing hydrogen peroxide as a by-product. The hydrogen
peroxide can then be electrochemically oxidized, and thus detected,
at interface point 130 on working electrode 100.
[0171] The membrane systems for use in the sensing biointerfaces
described herein may be any single- or multiple-component membrane
that enhances detection of the desired analyte. Some embodiments of
membranes useful for glucose detection are disclosed in U.S.
application Ser. No. 10/153,356, filed on May 22, 2002, which is
incorporated herein by reference in its entirety.
[0172] In the embodiment of FIGS. 6A to 6C, the working 100,
counter 102, and reference electrodes 104 are incorporated within
non-conductive layers 106, 108, 110, and 112. Thus, all of the
electrodes are internal to the sensing biointerface 90.
Alternatively, only the working electrode 100 is internal to the
biointerface 150. As in the embodiment of FIGS. 6A to 6C, the
optional counter electrode 102 and reference electrode 104 are
separated from the working electrode 100 by non-conductive layers
106 and 108. Alternatively, reference and/or counter electrode(s)
can be external to the device (e.g., not implanted) and may exist
in any known configuration as is appreciate by one skilled in the
art. However, additional non-conductive layers are not provided on
the tissue sides of the counter 102 and reference 104 electrodes.
This configuration is advantageous because the total number of
layers are decreased, thus simplifying manufacture. Furthermore,
because the counter electrode 102 will have one surface exposed to
surrounding tissue without being blocked by one of the
non-conductive layers, it will have a much greater surface area
exposed to the extracellular electrolyte solution, thus decreasing
its impedance and lowering solution resistance. In such an
alternative embodiment wherein reference and counter electrodes are
on external (tissue-facing) surfaces of the biointerface, the
membrane system can be coated onto the exterior surfaces and of the
counter electrode 102 and 104 respectively, if desired, in addition
to the interior surfaces of pores the 114.
[0173] It will be appreciated that the working, reference, and
optional counter electrodes may be placed in any location within
the sensing biointerfaces described herein. However, it is
advantageous to place the working electrode within the interior of
the sensing biointerface so that it will be exposed to the optimal
cell-disrupted FBR environment. Such a placement inhibits the
formation of a barrier cell layer on the working electrode.
[0174] Some embodiments of the present invention relate to methods
for manufacturing a sensing biointerface such as depicted in FIGS.
6A to 6C. Because the general structure of these biointerfaces is a
plurality of planar layers deposited on top of each other,
manufacturing can be done using any of a number of known techniques
for manufacturing multi-layer thin or thick film structures. For
example, techniques typically used in semiconductor manufacturing
may be applied. FIG. 7 depicts a flowchart of one process sequence
that can be used. At block 200, the first layer of the biointerface
is deposited onto a substrate. The substrate may be any suitable
surface such as glass or plastic. In one advantageous embodiment,
the substrate allows for easy removal of the biointerface after
manufacturing is complete. In one embodiment, the substrate
comprises polytetrafluoroethylene. The first layer deposited onto
the substrate may be either a non-conductive layer or a conductive
layer, depending on the desired final configuration of layers. For
example, in the embodiment of FIGS. 6A to 6C, the first layer may
be non-conductive layer 110. Alternatively, the first layer may be
counter electrode 102. At block 202, an additional layer is
deposited onto the first layer. The composition of the additional
layer depends on the final desired configuration. At decision block
204, it is determined whether additional layers are required. If
so, the process returns to block 202 for the deposition of a new
layer. The process continues until all desired layers have been
deposited. Then, at block 206, an interconnected pore structure is
induced into the structure. The interconnected pore structure may
be induced by any method known in the art for generating pore
structures. In one embodiment, the pores are generated by chemical
etching of the layered structure. In another embodiment, porosity
is generated by plasma etching of the layered structure. At block
208, a membrane system is deposited on all exposed surfaces if
desired. Any suitable method for depositing the membrane system may
be used, including but not limited to dip coating and vapor
deposition. Where the membrane system comprises multiple layers,
such as an enzyme layer and a polymeric diffusion layer, the layers
can be deposited sequentially. Finally, at block 210, the completed
biointerface is removed from the substrate and incorporated with
the other components required for the biosensor, such as sensing
electronics and a power source.
[0175] It will be appreciated that the method illustrated in FIG. 7
may be modified as desired. For example, it may be advantageous to
remove the biointerface from the substrate at an earlier step, such
as prior to deposition of a membrane system. Furthermore, it may be
advantageous to induce porosity in some of the deposited layers
prior to deposition of all of the layers.
[0176] Deposition of each layer may be by any suitable deposition
technique. Non-limiting examples of deposition techniques include
dip coating, vapor deposition, sputtering, lamination, brush
application, thick film, spin coating, and ink jet application. In
some embodiments, different deposition techniques are used for
different layers.
[0177] In some embodiments, photolithography techniques may be used
to define the location and size of pore openings in the surface of
the biointerface. For example, masks may be applied on one or more
of the surfaces of the biointerface and appropriate pore openings
photolithographically defined. Etching may then induce pore
formation into the biointerface through the photolithographically
defined openings. Finally, the masks can be removed by an
appropriate etch process. In one embodiment, pore openings are
defined in a regular array on the surfaces of the biointerface. In
one embodiment, when the counter electrode and reference electrode
comprise the outer surface of the biointerface, such as the
embodiment of FIG. 6B, they can be used as masks in the porosity
inducing etch step.
[0178] FIGS. 8A and 8B depict cross-sectional views of other
embodiments of a sensing biointerface. In FIG. 8A, a mesh structure
or scaffolding 250 is provided. Incorporated within the mesh
structure 250 are working electrode 100, counter electrode 102, and
reference electrode 104. In some embodiments, the mesh structure
250 consists of non-woven fibers. In other embodiments, the mesh
structure 250 consists of woven fibers. The fibers of mesh
structure 250 may be electrically non-conductive in order to
insulate the electrodes 100, 102, and 104 from each other. However,
in one embodiment, the mesh structure 250 is constructed of an
electrically conductive material, such a metal threading, that is
then coated with a non-conductive material. The mesh structure 250
provides spaces in between the fibers for FBR tissue in-growth,
however, barrier cell layers are disrupted as is depicted in FIG.
2. Analyte sensing can occur at any location 252 where the surface
of working electrode 102 interfaces with an opening between the
mesh fibers. If desired the electrodes 100, 102, and 104 may be
coated with a membrane system as described herein. In the
alternative embodiment of FIG. 8B, working electrode 100 is still
embedded within mesh 250; however, counter electrode 102 and
reference electrode 104 are deposited onto the surfaces of the mesh
structure 250.
[0179] Non-limiting examples of fibers that may be used for mesh
structure 250 include polypropylene, polytetrafluoroethylene,
polyvinylchloride, polyvinylidene fluoride, polybutylene
terephthalate, polymethylmethacrylate, polyether ether ketone,
polyurethanes, polyolefins, polyesters, polycarbonates, cellosic
polymers, polysulfones, and block copolymers thereof including, for
example, di-block, tri-block, alternating, random, and graft
copolymers. In some embodiments, non-woven fibers are greater than
about 5 microns in the shortest dimension. In some embodiments,
non-woven fibers are greater than about 10 microns in the shortest
dimension.
[0180] The electrodes 100, 102, and 104 are formed from
electrically conductive mesh, wires, or other porous structure such
that tissue grows therebetween, which together with the insulating
mesh structure 250, forms the sensing biointerface configured for
substantial tissue ingrowth including a mature bed of
vascularization.
[0181] It will be appreciated that other methods besides inducing
porosity and using mesh structures can be used to form matrixes
that comprise passageways from the exterior of the matrix to a
working electrode disposed within the matrix. Thus, many other
sensing biointerface structures are within the scope of this
disclosure.
[0182] For example, in one alternative embodiment, a biointerface
matrix, also referred to as a biocompatible matrix, surrounds a
sensing mechanism. FIG. 9A depicts a schematic surface view of a
porous biointerface 300 that surrounds a sensing mechanism 302. The
sensing mechanism may include a working electrode, with or without
a membrane system as described herein. In some embodiments, the
sensing mechanism may also include a reference and/or counter
electrode. Reference and/or Counter electrode(s) may also be
incorporated into the biointerface matrix and/or provided external
to the biointerface matrix as described elsewhere herein.
[0183] In some embodiments, the sensing mechanism does not itself
include passageways or pores, but rather is sized small enough
(e.g., in at least one dimension) and/or incorporated into the
biointerface matrix in such a way so as to manage the foreign body
response with the biointerface matrix to resist barrier cell
formation and allow the transport of analytes to the sensing
mechanism long-term (e.g., 1 day to 1 year or more). For example,
in some embodiments, at least one dimension of the sensing
mechanism may be sized similarly to the size of passageways or
structures within the non-sensing portion of the biointerface
matrix (e.g., pore diameter of a porous structure or fiber diameter
of a fibrous structure). In one embodiment, the sensing mechanism
has a size in at least one dimension of less than about 1000
microns, however other configurations are possible. In some
embodiments, both the biointerface matrix and the sensing mechanism
are substantially indistinguishable to cells in a host's biological
response, such that cells grow in and around the sensing
biointerface substantially without barrier cells, thereby enabling
sensing of the analyte (e.g., glucose) throughout the sensing
biointerface for a long time (e.g., from days to years).
[0184] In the embodiment illustrated in FIG. 9A of a porous
biointerface matrix, also referred to as a biocompatible matrix, a
substantial number of the cavities may be greater than or equal to
about 20 microns in one dimension (e.g., a substantial number of
the cavities are greater than or equal to about 30, 40, 50, 60, 70,
80, 90, 100, 120, 140, 160, 180, 200, 240, 280, 320, 360, 400, 500,
600, 700 microns in one dimension). In some embodiments, a
substantial number of the cavities are less than or equal to about
1000 microns in one dimension (e.g., a substantial number of the
cavities are less than or equal to about 900, 800, 700, 600, 500,
400, 360, 320, 280, 240, 200, 180, 160, 140, 120, 100 microns in
one dimension.) Although FIG. 9A illustrates a porous biointerface
matrix, in some embodiments, the biocompatible matrix includes
non-woven materials, woven materials, or other such materials, such
that a porous structure is formed from the cavities between the
fibers. In these embodiments, for example, the fibers are formed by
structural elements that provide the three-dimensional
conformation. Therefore in these embodiments, the biocompatible
matrix may be defined by a fiber size of between about 1 and 100
microns in all but the longest dimension and a sufficient number of
cavities of a size and structure to allow inflammatory cells (for
example, macrophages) to completely enter therein through the
apertures that define the cavities.
[0185] A variety of sensing mechanisms having the characteristics
described above can be incorporated into a biointerface matrix. For
example, in some embodiments, the sensing mechanism is a wire
structure, with or without membrane systems as described herein.
FIG. 9B depicts a longitudinal cross-section of one exemplary
wire-type sensor. The wire-type sensor in FIG. 9B includes a
working electrode wire 306 with exposed electroactive portions 308.
The electroactive portions 308 are optionally coated with a
membrane system as described herein. Although a wire-type sensor is
described herein, the sensing biointerface of the preferred
embodiments can utilize other appropriately sized sensors, for
example, a planar substrate-based sensor such as described in U.S.
Pat. No. 6,565,509, which is incorporated herein by reference in
its entirety.
[0186] The electrode 306 is formed from a fine wire with a diameter
of from about 0.001 inches or less to about 0.010 inches or more.
In preferred embodiments, the working electrode 306 comprises a
wire formed from a conductive material, such as platinum,
platinum-iridium, palladium, graphite, gold, carbon, conductive
polymer, alloys, or the like. Although the electrodes can by formed
by a variety of manufacturing techniques (bulk metal processing,
deposition of metal onto a substrate, or the like), it can be
advantageous to form the electrodes from plated wire (e.g.,
platinum on steel wire) or bulk metal (e.g., platinum wire). It is
believed that an electrode formed from bulk metal wire provide
superior performance (e.g., in contrast to deposited electrodes),
including increased stability of assay, simplified
manufacturability, resistance to contamination (e.g., which can be
introduced in deposition processes), and improved surface reaction
(e.g., due to purity of material) without peeling or
delamination.
[0187] In some embodiments, the working electrode 306 is covered
with an insulating material 312, for example, a non-conductive
polymer. Dip-coating, spray-coating, vapor-deposition, or other
coating or deposition techniques can be used to deposit the
insulating material on the working electrode. In one embodiment,
the insulating material comprises parylene, which can be an
advantageous polymer coating for its strength, lubricity, and
electrical insulation properties. Generally, parylene is produced
by vapor deposition and polymerization of para-xylylene (or its
substituted derivatives). While not wishing to be bound by theory,
it is believed that the lubricious (e.g., smooth) coating (e.g.,
parylene) on the sensors of the preferred embodiments contributes
to minimal trauma and extended sensor life. However, an insulator
material is not required.
[0188] In embodiments wherein an outer insulator 312 is used,
portion(s) of the coated assembly structure can be stripped or
otherwise removed, for example, by hand, excimer lasing, chemical
etching, laser ablation, grit-blasting (e.g., with sodium
bicarbonate or other suitable grit), or the like, to expose the
electroactive surfaces 308. Alternatively, a portion of the
electrode can be masked prior to depositing the insulator in order
to maintain an exposed electroactive surface area 308. In one
exemplary embodiment, grit blasting is implemented to expose the
electroactive surfaces 308, preferably utilizing a grit material
that is sufficiently hard to ablate the polymer material, while
being sufficiently soft so as to minimize or avoid damage to the
underlying metal electrode (e.g., a platinum electrode). Although a
variety of "grit" materials can be used (e.g., sand, talc, walnut
shell, ground plastic, sea salt, and the like), in some preferred
embodiments, sodium bicarbonate is an advantageous grit-material
because it is sufficiently hard to ablate, e.g., a parylene coating
without damaging, e.g., an underlying platinum conductor. One
additional advantage of sodium bicarbonate blasting includes its
polishing action on the metal as it strips the polymer layer,
thereby eliminating a cleaning step that might otherwise be
necessary.
[0189] In some alternative embodiments, multiple electrodes can be
included within the sensing biointerface 300. For example, a
three-electrode system (working, reference, and counter electrodes)
and/or additional working electrode(s) (e.g., an electrode which
can be used to generate oxygen, which is configured as a baseline
subtracting electrode, or which is configured for measuring
additional analytes). U.S. Publication No. US-2005-0161346-A1 and
U.S. Publication No. US-2005-0143635-A1 describe some systems and
methods for implementing and using additional working, counter,
and/or reference electrodes. The resulting electrode system can be
configured with an appropriate membrane system, such as the
membranes described herein, wherein the first working electrode is
configured to measure a first signal comprising glucose and
baseline and the additional working electrode is configured to
measure a baseline signal consisting of baseline only (e.g.,
configured to be substantially similar to the first working
electrode without an enzyme disposed thereon). In this way, the
baseline signal can be subtracted from the first signal to produce
a glucose-only signal that is substantially not subject to
fluctuations in the baseline and/or interfering species on the
signal.
[0190] A membrane system can be deposited on the exposed
electroactive surfaces (and/or portions or entirety of sensing
mechanism) using known thin film techniques (for example, vapor
deposition, spraying, electro-depositing, dipping, or the like) as
described in more detail elsewhere herein.
[0191] In some embodiments, the biointerface matrix 304 may be
formed around wire electrode(s) or other electrodes using a
pre-formed shape and structure. In some embodiments, the sensing
biointerface can be manufactured by forming particles (e.g., sugar,
salt, or other natural or synthetic uniform or non-uniform
particles) in a mold including the sensing mechanism (e.g., a wire
electrode), wherein the particles have shapes and sizes
substantially corresponding to the desired cavity dimensions. Most
often, the particles are made to coalesce within the mold (e.g.
around the sensing mechanism) to provide the desired
interconnectivity between the cavities.
[0192] The desired material for the solid portion (e.g., silicone,
elastomeric conductive carbon, and the like) can be introduced into
the mold using methods common in the art of polymer processing, for
example injecting, pressing, vacuuming, or pouring, while taking
care to work with the sensing mechanism within the mold. After the
solid portion material is cured or solidified, the coalesced
particles are then dissolved, melted, etched, or otherwise removed
leaving interconnecting cavities within the solid portion.
[0193] Accordingly, the nominal cavity size of the cavities of the
biointerface matrix can be substantially defined by the particle
size used in creating the cavities. It is noted that in some
embodiments, the particles used to form the cavities can be
substantially spherical, thus the dimensions below describe a
diameter of the particle and/or a diameter of the cavity. In some
alternative embodiments, the particles used to form the cavities
can be non-spherical (e.g., rectangular, square, diamond, or other
geometric or non-geometric shapes), thus the dimensions below
describe one dimension (e.g., shortest, average, or longest, for
example) of the particle and/or cavity.
[0194] In some embodiments, a variety of different particle sizes
can be used in the manufacture of the biointerface matrix. In some
embodiments, the dimensions of the particles can be somewhat
smaller or larger than the dimensions of the resulting cavities due
to dissolution or other precipitation that can occurring during the
manufacturing process, for example.
[0195] One preferred material that can be used to form the solid
portion of the biointerface matrix is a material that allows the
passage of the analyte (e.g., glucose) therethrough. For example,
the biointerface matrix may be formed from a silicone
polymer/hydrophobic-hydrophilic polymer blend. In one embodiment,
The hydrophobic-hydrophilic polymer for use in the blend may be any
suitable hydrophobic-hydrophilic polymer, including but not limited
to components such as polyvinylpyrrolidone (PVP), polyhydroxyethyl
methacrylate, polyvinylalcohol, polyacrylic acid, polyethers such
as polyethylene glycol or polypropylene oxide, and copolymers
thereof, including, for example, di-block, tri-block, alternating,
random, comb, star, dendritic, and graft copolymers (block
copolymers are discussed in U.S. Pat. Nos. 4,803,243 and 4,686,044,
which are incorporated herein by reference). In one embodiment, the
hydrophobic-hydrophilic polymer is a copolymer of poly(ethylene
oxide) (PEO) and poly(propylene oxide) (PPO). Suitable such
polymers include, but are not limited to, PEO-PPO diblock
copolymers, PPO-PEO-PPO triblock copolymers, PEO-PPO-PEO triblock
copolymers, alternating block copolymers of PEO-PPO, random
copolymers of ethylene oxide and propylene oxide, and blends
thereof. In some embodiments, the copolymers may be optionally
substituted with hydroxy substituents. Commercially available
examples of PEO and PPO copolymers include the PLURONIC.RTM. brand
of polymers available from BASF.RTM.. In one embodiment,
PLURONIC.RTM. F-127 is used. Other PLURONIC.RTM. polymers include
PPO-PEO-PPO triblock copolymers (e.g., PLURONIC.RTM. R products).
Other suitable commercial polymers include, but are not limited to,
SYNPERONICS.RTM. products available from UNIQEMA.RTM..
[0196] The silicone polymer for use in the
silicone/hydrophobic-hydrophilic polymer blend may be any suitable
silicone polymer. In some embodiments, the silicone polymer is a
liquid silicone rubber that may be vulcanized using a metal- (e.g.,
platinum), peroxide-, heat-, ultraviolet-, or other
radiation-catalyzed process. In some embodiments, the silicone
polymer is a dimethyl- and methylhydrogen-siloxane copolymer. In
some embodiments, the copolymer has vinyl substituents. In some
embodiments, commercially available silicone polymers may be used.
For example, commercially available silicone polymer precursor
compositions may be used to prepare the blends, such as described
below. In one embodiment, MED-4840 available from NUSIL.RTM.
Technology LLC is used as a precursor to the silicone polymer used
in the blend. MED-4840 consists of a 2-part silicone elastomer
precursor including vinyl-functionalized dimethyl- and
methylhydrogen-siloxane copolymers, amorphous silica, a platinum
catalyst, a crosslinker, and an inhibitor. The two components may
be mixed together and heated to initiate vulcanization, thereby
forming an elastomeric solid material. Other suitable silicone
polymer precursor systems include, but are not limited to, MED-2174
peroxide-cured liquid silicone rubber available from NUSIL.RTM.
Technology LLC, SILASTIC.RTM. MDX4-4210 platinum-cured biomedical
grade elastomer available from DOW CORNING.RTM., and Implant Grade
Liquid Silicone Polymer (durometers 10-50) available from Applied
Silicone Corporation.
[0197] Silicone polymer/hydrophobic-hydrophilic polymer blends are
described in more detail in U.S. patent application Ser. No.
11/404,417, entitled "SILICONE BASED MEMBRANES FOR USE IN
IMPLANTABLE GLUCOSE SENSORS," filed on Apr. 14, 2006, which is
incorporated herein by reference in its entirety.
[0198] Although one method of manufacturing porous domains is
described above, a variety of methods known to one of ordinary
skill in the art can be employed to create the structures of
preferred embodiments. For example, molds can be used in the place
of the particles described above, such as coral, self-assembly
beads, etched or broken silicon pieces, glass frit pieces, and the
like. The dimensions of the mold can define the cavity sizes, which
can be determined by measuring the cavities of a model final
product, and/or by other measuring techniques known in the art, for
example, by a bubble point test. In U.S. Pat. No. 3,929,971, Roy
discloses a method of making a synthetic membrane having a porous
microstructure by converting calcium carbonate coral materials to
hydroxyapatite while at the same time retaining the unique
microstructure of the coral material.
[0199] Other methods of forming a three-dimensional biointerface
matrix can be used, for example holographic lithography,
stereolithography, and the like, wherein cavity sizes are defined
and precisely formed by the lithographic or other such process to
form a lattice of unit cells, as described in Published U.S. Patent
Application 2005-0251083, entitled "Macro-Micro Architecture for
Biointerface Membrane," which is incorporated herein by reference
in its entirety and as described by Pekkarinen et al. in U.S. Pat.
No. 6,520,997, which discloses a photolithographic process for
creating a porous membrane. In another embodiment, the biointerface
matrix can "written" using computer-aided manufacturing techniques.
In one such example, the biointerface matrix is fabricated by
dispensing of very small volumes of liquid silicone rubber (LSR),
by a robot, onto a heated platform, in an array called out by a
CAD-like code programmed into the computer controlling the robot,
whereby layers of LSR would be added onto the structure as the
layers beneath them are cured by the heat. One such method has been
disclosed in U.S. Published Patent Application No. 2004-0253365-A1
entitled "Architecture Tool and Methods of Use," which is
incorporated herein by reference in its entirety. Alternatively,
the biointerface matrix includes non-woven materials, woven
materials, or other such materials, such that a porous structure is
formed from the cavities between the fibers. In any of the above
methods of forming the biointerface matrix, the matrix can be
formed around a sensing mechanism as illustrated with reference to
FIG. 9A. FIGS. 10 to 14 are flowcharts illustrating various
exemplary processes for obtaining a structure having a biointerface
matrix surrounding a sensing mechanism, such as depicted in FIG.
9A.
[0200] FIG. 10 is a flow chart that illustrates the process 151 of
forming a biointerface-coated small structured sensing mechanism in
one embodiment. In this embodiment, the biointerface matrix
includes woven or non-woven fibers formed directly onto the sensing
mechanism. Generally, fibers can be deposited onto the sensing
mechanism using methods suitable for formation of woven- or
non-woven fibrous materials. In some embodiments, the biointerface
matrix is electrospun directly onto the sensing mechanism;
electrospinning advantageously allows the biointerface matrix to be
made with small consistent fiber diameters that are fused at the
nodes and are without aggregation. In some embodiments, the
biointerface matrix is directly written onto the sensing mechanism;
direct-writing can advantageously allow uniform deposition of
stored patterns for providing consistent and reproducible
architectures.
[0201] At block 153, one or more dispensers dispense a polymeric
material used to form the fibers, such as any of the polymeric
materials described herein. The coating process can be performed in
a vacuum or in a gaseous medium, which environment may affect the
architecture of the biointerface matrix as is appreciated by one
skilled in the art.
[0202] In embodiments wherein the biointerface is electrospun onto
the sensing mechanism, the dispenser dispenses a charged liquefied
polymer within an electric field, to thereby form a jet of polymer
fibers, for example, such as described in International Published
Patent Application No. WO 2005/032400, which is incorporated herein
by reference in its entirety. In embodiments wherein the
biointerface is directly-written onto the sensing mechanism, the
dispenser dispenses a polymer solution using a nozzle with a valve,
or the like, for example as described in U.S. Published Patent
Application No. 2004/0253365, which is incorporated herein by
reference in its entirety. In general, a variety of nozzles and/or
dispensers can be used to dispense a polymeric material to form the
woven or non-woven fibers of the biointerface matrix.
[0203] At block 154, the dispenser(s) is moved relative to the
sensing mechanism and/or the sensing mechanism is moved relative to
the dispenser(s) so as to coat the sensing mechanism with the
fibers. In embodiments wherein the biointerface matrix is
electrospun onto the sensing mechanism, the dispenser(s) can change
the direction and/or magnitude of the electric field during motion
in order to effect the orientation of the polymer fibers on the
sensing mechanism. Additionally, the path of the dispenser is
preferably selected so as to coat the portions of or the entire
object. In one exemplary embodiment, wherein it is desirable for
the biointerface matrix to substantially circumscribe the sensing
mechanism (e.g., a substantially cylindrical shape), such as
illustrated in FIG. 9C described below, the dispenser can be moved
along a helix path, a circular path, a zigzag path, or the like.
Additionally, the dispenser can move rotationally and/or
translationally relative to the sensing mechanism. The number of
sweeps is preferably selected according to the desired architecture
of the biointerface matrix. Additionally, the density of the fibers
and/or the type of liquefied polymer can be changed from one sweep
to the other to thereby control the architecture of the
membrane.
[0204] In embodiments where the biointerface matrix is directly
written onto the sensing mechanism, the dispenser may be programmed
to write a pattern that creates the desired membrane architecture,
including the interconnected cavities and solid portion(s). Namely,
the dispenser is programmed to move in the x, y, and optionally z
direction in order to create the desired membrane architecture.
See, for example, U.S. Published Patent Application No.
2004/0253365 cited above.
[0205] Although the preferred embodiments described moving the
dispenser(s) relative to the sensing mechanism, alternatively, the
dispenser can remain stationary and the sensing mechanism moved, as
is appreciated by one skilled in the art.
[0206] In some embodiments, the sensing mechanism is moved in a
rotational or translational motion, which can be performed in
combination with, or instead of, movement of the dispenser. In this
step, the sensing mechanism is moved so as to ensure coating
throughout the entirety of the biointerface region (or a portion
thereof). In one exemplary embodiment, wherein a substantially
circumscribing biointerface matrix is desired (e.g., for a
substantially cylindrically shaped sensing mechanism) such as
illustrated in FIG. 9C, the sensing mechanism can be rotated so to
aid in coating the entire circumference of the sensing mechanism.
In another exemplary embodiment, wherein a substantially planar
biointerface matrix is desired (e.g., for a substantially planar
sensing mechanism), the sensing mechanism can be translated so as
to aid in coating the desired planar surface area.
[0207] FIG. 11 is a flow chart that illustrates the process 160 of
forming a biointerface-coated sensing mechanism in an alternative
embodiment. In this embodiment, the biointerface matrix is porous
in configuration, such as illustrated in FIG. 3, for example.
[0208] At block 162, a selectively removable porous mold is formed
by spraying, coating, rolling, or otherwise forming selectively
removable particles, for example, sugar crystals, onto the surface
of the sensing mechanism. Additional examples of materials suitable
as selectively removable mold material include thermoplastic
polymers such as waxes, paraffin, polyethylene, nylon,
polycarbonate, or polystyrene in naturally available particles or
processed into specific sizes, shapes, molded forms, spheres or
fibers, salt or other particles which cannot be made to inherently
stick together coated with sugar, and certain drug crystals such as
gentamycin, tetracycline, or cephalosporins. In general, any
dissolvable, burnable, meltable, or otherwise removable particle
which can be made to stick together could be used. Preferably, the
particles have shapes and sizes substantially corresponding to the
desired cavity dimensions, such as described in more detail above.
In some embodiments, the particles are made to adhere to the
sensing mechanism by environmental conditions, for example,
humidity can be used to cause sugar to adhere to the sensing
mechanism.
[0209] In some embodiments, the particles are made to coalesce to
provide the desired interconnectivity between the cavities. In an
exemplary porous silicone embodiment, sugar crystals are exposed to
a humid environment sufficient to cause coalescence of the sugar
crystals. In some alternative embodiments, other molds may be used
in the place of the particles described above, for example, coral,
self-assembly beads, etched and broken silicon pieces, glass frit
pieces, and the like.
[0210] At block 164, a material (e.g., a moldable or conformable
material) is filled or coated into the interconnected cavities of
the mold using methods common in the art of polymer processing, for
example, injecting, pressing, vacuuming, vapor depositing, pouring,
and the like. Examples of materials suitable for the resulting
porous device include polymers, metals, metal alloys, ceramics,
biological derivatives, and combinations thereof, in solid or fiber
form. In an exemplary porous silicone embodiment, silicone is
pressed into the interconnected cavities of the mold.
[0211] At block 166, the material is substantially cured or
solidified to form the solid portion(s) of the biointerface matrix.
Solidification of the material can be accelerated by supplying dry
air (which may be heated) to the material, for example.
Additionally, freezing, freeze drying or vacuum desiccation, with
or without added heat, may also be utilized to cause the material
to solidify. In some circumstances, a skin or any excess material
can be removed (e.g., shaved, etched, or the like) after curing. In
the exemplary porous silicone embodiment, an outer skin of silicone
is removed to expose the interconnected cavities at an outer
surface.
[0212] At block 168, the selectively removable porous mold is
dissolved, melted, etched, or otherwise removed, leaving
interconnecting cavities within the solid portion. Preferably, the
selectively removable porous mold is readily removable without
significantly altering the final product (or product material).
This removal may be by dissolution by some solvent that does not
significantly dissolve the final product material. Alternatively,
the mold material may be melted (or burned) out of the final
product material if the melting point (or burning point) of the
mold material is below that of the final product material. In the
exemplary porous silicone embodiment, water is used to dissolve the
sugar crystals.
[0213] FIG. 12 is a flow chart that illustrates the process 170 of
forming a biointerface-coated small structured sensing mechanism in
another alternative embodiment. In this embodiment, the
biointerface matrix is porous in configuration, such as illustrated
in FIG. 3, for example.
[0214] At block 172, a selectively removable porous mold is formed
by filling a shaped cavity with selectively removable particles,
for example, sugar crystals, wherein the sensing mechanism is
located within the shaped cavity, and wherein the selectively
removable particles substantially surround the sensing mechanism.
Additional examples of materials suitable as selectively removable
mold material are described with reference to block 162, above. In
some embodiments, the shaped cavity mold is formed from a
selectively removable material (e.g., sacrificial cavity mold)
similar the selectively removable particles described above. One
such example includes a tube formed from a dissolvable polymer.
Alternatively, the shaped cavity can be a non-selectively removable
material, and instead, a sacrificial layer of selectively removable
material is formed directly onto the cavity walls, enabling the
removal of the biointerface matrix after dissolution of the
sacrificial layer.
[0215] Preferably the shape of the cavity mold substantially
corresponds to the desired final shape of the biointerface matrix.
In one exemplary embodiment, the cavity mold is substantially
cylindrical, for example using a syringe or cannula as the cavity
mold.
[0216] In some embodiments, the particles are made to coalesce to
provide the desired interconnectivity between the cavities. In an
exemplary porous silicone embodiment, sugar crystals are exposed to
humidity or spray of water sufficient to cause coalescence of the
sugar crystals. In some alternative embodiments, other molds may be
used in the place of the particles described above, for example,
coral, self-assembly beads, etched and broken silicon pieces, glass
frit pieces, and the like.
[0217] At block 174, a material (e.g., a moldable or conformable
material) is filled into the interconnected cavities of the mold
using methods common in the art of polymer processing, for example,
injecting, pressing, vacuuming, vapor depositing, pouring, and the
like. Examples of materials suitable for the resulting porous
device are described in more detail with reference to block 164,
above. In an exemplary porous silicone embodiment, silicone is
pressed into the interconnected cavities of the mold.
[0218] At block 176, the material is substantially cured or
solidified to form the solid portion(s) of the biointerface matrix.
Solidification of the material can be accelerated as described in
more detail with reference to block 166, above.
[0219] At block 178, the selectively removable porous mold is
dissolved, melted, etched, or otherwise removed, leaving
interconnecting cavities within the solid portion surrounding the
sensing mechanism. In some embodiments, wherein a sacrificial layer
is formed as described above, the sacrificial layer can be remove
before, during, or after the removal of the selectively removable
porous mold. In some embodiments, the final product is removed from
the cavity mold before, during, or after the removal of the
selectively removable porous mold.
[0220] Preferably, the selectively removable porous mold is readily
removable without significantly altering the final product (or
product material). This removal may be by dissolution by some
solvent that does not significantly dissolve the final product
material. Alternatively, the mold material may be melted (or
burned) out of the final product material if the melting point (or
burning point) of the mold material is below that of the final
product material. In one exemplary embodiment, a sacrificial tube
forms the mold cavity; wherein the sacrificial tube is removed
prior to, during, or after dissolution of the selectively removable
porous mold. One skilled in the art can appreciate a variety of
modifications or combinations of the above described removal step
without departing from the spirit of the invention.
[0221] FIG. 13 is a flow chart that illustrates the process 180 of
forming a biointerface-wrapped sensing mechanism in one embodiment.
In this embodiment, the interconnected cavities and solid
portion(s) of the biointerface matrix can be fibrous or porous in
configuration. In fact, substantially any biointerface matrix with
an architecture as described in more detail above, which is formed
in substantially any manner, can be used with this embodiment.
[0222] At block 182, a sensing mechanism is manufactured and
provided, wherein the sensing mechanism is formed with a small
structure as discussed above.
[0223] At block 184, a biointerface membrane with an architecture
as described herein is manufactured in substantially any desired
manner, wherein the biointerface membrane is formed substantially
as a sheet or tube of membrane.
[0224] At block 186, the biointerface membrane is wrapped around
the sensing mechanism manually, or using an automated device, as
can be appreciated by one skilled in the art. Namely, the
biointerface membrane is wrapped such that it substantially
surrounds the sensing mechanism. The number of wraps can be from
less than 1 to about 100, preferably 1, 11/2, 2, 21/2, 3, 31/2, 4,
5, 6, 7, 8, 9, 10, or more. The number of wraps depends on the
architecture of the sheet of biointerface membrane, and the desired
architecture of the biointerface surrounding the sensing
mechanism.
[0225] In some embodiments, the circumference (or a portion thereof
(e.g., an edge)) of the biointerface membrane with an architecture
as described herein can be adhered or otherwise attached or sealed
to form a substantially consistent outer surface (of the
biointerface membrane). In an aspect of this embodiment, the
biointerface membrane is wrapped around the sensing mechanism one
time, wherein the "wrap" includes a tubular biointerface membrane
configured to slide over the sensing mechanism, for example, be
stretching the tubular biointerface membrane and inserting the
sensing mechanism therein.
[0226] FIG. 14 is a flow chart that illustrates the process 190 of
forming a sensing biointerface in one embodiment. In this
embodiment, the sensing mechanism is inserted into the biointerface
matrix so that it is encompassed therein.
[0227] At block 192, a biointerface matrix is manufactured in
substantially any desired manner, such as the methods described
above. In some embodiments, the biointerface matrix is molded into
the desired final shape to surround the sensing mechanism and
implant into a host. Alternatively, the biointerface matrix can be
provided as a sheet of bulk material.
[0228] At block 194, a particularly shaped or sized biointerface
matrix can be optionally cut. Namely, in embodiments wherein the
biointerface matrix is provided in bulk, e.g., as a sheet of
material, the desire shape or size can be cut therefrom. In these
embodiments, bulk biointerface matrix sheet is preferably of the
appropriate thickness for the desired final product. In one
exemplary embodiment, the biointerface matrix (bulk sheet) is
compressed, for example between two substantially rigid structures,
and the final size/shape biointerface matrix cut there from, after
which the biointerface matrix is released. While not wishing to be
bound by theory, it is believed that by compressing the
biointerface matrix during cutting, a more precise shape can be
achieved. It is noted that biointerface matrix can have sufficient
elasticity, such that the thickness is returned after release from
compression, as is appreciated by one skilled in the art.
[0229] At block 196, a sensing mechanism is inserted into the
biointerface matrix. Preferably, the sensing mechanism is inserted
into the membrane such that the sensing mechanism contacts at least
one or more of the interconnected cavities so that the host analyte
can be measured. Alternatively, the biointerface can be formed from
a material that allows the flux of the analyte there through. In
some embodiments, the sensing mechanism is inserted with the aid of
a needle. Alternatively, the sensing mechanism is formed with
appropriate sharpness and rigidity to enable insertion through the
biointerface matrix.
[0230] In some embodiments, an anchoring mechanism, such as a barb,
is provided on the sensing mechanism, in order to anchor the
sensing mechanism within the biointerface matrix (and/or host
tissue). A variety of additional or alternative aspects can be
provided to implement the biointerface matrix surrounded sensing
mechanisms of the preferred embodiments.
[0231] All of the above manufacturing techniques can be used to
form the sensing biointerface around a sensing mechanism, as is
appreciated by one skilled in the art. Additionally, the sensing
biointerface of the preferred embodiments can be implemented in a
variety of shapes, sizes, and configurations and with any number of
electrodes and electrode configurations. The figures below (FIGS.
9C to 9G) describe a few exemplary embodiments.
[0232] FIG. 9C is a schematic cross-sectional view of a sensing
biointerface in one embodiment, including a single wire sensor 306
incorporated into a cylindrical shaped biointerface matrix 300
(shown in a side-view cross-section). In one exemplary embodiment,
the biointerface is formed as described above, within a cylindrical
mold. Although a method of molding the sensing mechanism into the
biointerface matrix is described above, other methods may include
manufacturing the sensing mechanism and biointerface separately and
then assembling them in a final step (e.g., pushing the wire
through the biointerface matrix (e.g., with a protective introducer
in some embodiments)). The use of a wire electrode provides
multiple sensing points along the length of the wire (either a
continuous series of sensing points due to an uninsulated length of
wire or discrete sensing points due to periodic removal of an
insulative coating as described above with reference to FIG. 9B).
Accordingly, blockage or dysfunction of certain sensing points
along the wire (e.g., due to cellular attack or other malfunction)
but not others will not affect the function of the overall
sensor.
[0233] FIG. 9D is a schematic cross-sectional view of a sensing
biointerface in another embodiment wherein the sensing biointerface
includes a plurality of electrodes 306 (e.g., in fork
configuration). For example, working, reference, and/or counter
wire electrodes may be separately disposed in the biointerface
matrix 300. In addition, multiple working electrodes may be used. A
variety of configurations are possible for implementing the
plurality of electrodes within the biointerface matrix. One
advantage of deploying multiple working electrodes within the
porous sensing biointerface is that some blockage or dysfunction on
one working electrode (e.g., due to cellular attack or other
malfunction) but not others will not affect the function of the
overall sensor. In addition, using multiple working wire electrodes
increases the overall number of sensing points along the combined
lengths of the wires. By using a fork configuration, the sensing
points are more widely distributed throughout the biointerface
matrix.
[0234] FIG. 9E is a schematic cross-sectional view of a sensing
biointerface in yet another embodiment wherein the sensing
biointerface comprises a spiral wire sensor 306. Similar to the
above-described plurality of electrodes, the spiral electrode
provides an increase distribution of sensing points throughout the
sensing biointerface, increasing the probability of good sensor
performance.
[0235] FIG. 9F is a schematic cross-sectional view of a sensing
biointerface in yet another embodiment wherein the electrode 306
forms a tortuous path within the biointerface matrix 300, again
increasing the distribution of sensing points.
[0236] FIG. 9G is a schematic cross-sectional view of a wholly
implantable analyte sensor 300 in one embodiment. The sensor 300
includes a sensor body 302 (e.g., for containing the electronics
described below) suitable for subcutaneous implantation. Published
U.S. Patent Application No. 2004/0199059 to Brauker et al.
describes systems and methods suitable for the sensor body 302, and
is incorporated herein by reference in its entirety. The sensor 300
also includes a small-structured sensing mechanism consisting of a
wire electrode 304 with a biointerface matrix coating 306. The
biointerface matrix 306 depicted in FIG. 9G is not necessarily
drawn to scale and may be any suitable size and shape when
surrounding wire electrode 304. In some embodiments, the wire
electrode 304 is coated with a membrane system such as described
herein.
[0237] One material that may be particularly suitable for either
the biointerface matrix and/or the electrode(s) of the sensing
mechanism of the preferred embodiments is elastomeric carbon.
Elastomeric carbon is a material that is both elastic, which is a
preferable property for the biointerface matrix, and is conductive,
which is a preferable property for the working electrode(s). Some
embodiments contemplate only a portion of the biointerface formed
from elastomeric carbon. Because the elastomeric carbon can be used
for the sensing mechanism and the biointerface matrix portions of
the sensing biointerface, manufacture of the sensing biointerface
is made simple. Namely, the biointerface matrix can be formed at
least in part from elastomeric carbon using any of the methods
described above, after which a membrane system can be directly
applied to at least portions thereof, enabling sensing of the
analyte. As one example of the elastomeric carbon embodiments
described above, the biointerface matrix is formed from woven or
non-woven material (e.g., ePTFE) over which elastomeric carbon or
other electrode material is deposited (e.g., sprayed), and over
which the membrane is deposited (e.g., vapor deposited). Although
one example has been suggested, a variety of implementations of the
sensing biointerface comprising elastomeric carbon (e.g., as a part
of the biointerface matrix and sensing mechanism) are contemplated
and included in the preferred embodiments.
[0238] In general, sterilization of the transcutaneous sensor can
be completed after final assembly, utilizing methods such as
electron beam radiation, gamma radiation, glutaraldehyde treatment,
or the like. The sensor can be sterilized prior to or after
packaging. In an alternative embodiment, one or more sensors can be
sterilized using variable frequency microwave chamber(s), which can
increase the speed and reduce the cost of the sterilization
process. In another alternative embodiment, one or more sensors can
be sterilized using ethylene oxide (EtO) gas sterilization, for
example, by treating with 100% ethylene oxide, which can be used
when the sensor electronics are not detachably connected to the
sensor and/or when the sensor electronics must undergo a
sterilization process.
Membrane Systems
[0239] As discussed above, in some embodiments, the sensing
biointerfaces described herein include membranes systems deposited
on one or more electroactive surfaces within the biointerface. In
some embodiments, one or more domains of the membrane systems are
formed from materials such as silicone, polytetrafluoroethylene,
polyethylene-co-tetrafluoroethylene, polyolefin, polyester,
polycarbonate, biostable polytetrafluoroethylene, homopolymers,
copolymers, terpolymers of polyurethanes, polypropylene (PP),
polyvinylchloride (PVC), polyvinylidene fluoride (PVDF),
polybutylene terephthalate (PBT), polymethylmethacrylate (PMMA),
polyether ether ketone (PEEK), polyurethanes, cellulosic polymers,
polysulfones and block copolymers thereof including, for example,
di-block, tri-block, alternating, random and graft copolymers.
Co-pending U.S. patent application Ser. No. 10/838,912, which is
incorporated herein by reference in its entirety, describes some
biointerface and membrane system configurations and materials that
may be applied to the preferred embodiments. Additional examples
are described below.
[0240] The membrane system can be deposited on the exposed
electroactive surfaces using known thin film techniques (for
example, vapor deposition, spraying, electro-depositing, dipping,
or the like). In alternative embodiments, however, other vapor
deposition processes (e.g., physical and/or chemical vapor
deposition processes) can be useful for providing one or more of
the insulating and/or membrane layers, including ultrasonic vapor
deposition, electrostatic deposition, evaporative deposition,
deposition by sputtering, pulsed laser deposition, high velocity
oxygen fuel deposition, thermal evaporator deposition, electron
beam evaporator deposition, deposition by reactive sputtering
molecular beam epitaxy, atmospheric pressure chemical vapor
deposition (CVD), atomic layer CVD, hot wire CVD, low-pressure CVD,
microwave plasma-assisted CVD, plasma-enhanced CVD, rapid thermal
CVD, remote plasma-enhanced CVD, and ultra-high vacuum CVD, for
example. However, the membrane system can be disposed over (or
deposited on) the electroactive surfaces using any known method, as
will be appreciated by one skilled in the art. It is noted that the
membrane system that surrounds the working electrode does not have
to be the same structure as the membrane system that surrounds a
reference electrode, etc. For example, the enzyme domain deposited
over the working electrode does not necessarily need to be
deposited over the reference and/or counter electrodes.
[0241] Electrode/Electrolyte Domain
[0242] In selected embodiments, the membrane system comprises an
electrode domain 56. The electrode domain 56 is preferably situated
more proximal to the electroactive surfaces than the interference
and/or enzyme domain. Preferably, the electrode domain includes a
coating that maintains a layer of water at the electrochemically
reactive surfaces of the sensor. For example, a humectant in a
binder material can be employed as an electrode domain; this allows
for the full transport of ions in the aqueous environment. The
electrode domain can also assist in stabilizing the operation of
the sensor by accelerating electrode start-up and drifting problems
caused by inadequate electrolyte. The material that forms the
electrode domain can also provide an environment that protects
against pH-mediated damage that can result from the formation of a
large pH gradient due to the electrochemical activity of the
electrodes.
[0243] In one embodiment, the electrode domain 56 includes a
flexible, water-swellable, hydrogel film having a "dry film"
thickness of from about 0.05 micron or less to about 20 microns or
more, more preferably from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3,
0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5
microns, and more preferably still from about 2, 2.5 or 3 microns
to about 3.5, 4, 4.5, or 5 microns. "Dry film" thickness refers to
the thickness of a cured film cast from a coating formulation by
standard coating techniques.
[0244] In certain embodiments, the electrode domain 56 is formed of
a curable mixture of a urethane polymer and a hydrophilic polymer.
Particularly preferred coatings are formed of a polyurethane
polymer having carboxylate or hydroxyl functional groups and
non-ionic hydrophilic polyether segments, wherein the polyurethane
polymer is crosslinked with a water soluble carbodiimide (e.g.,
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)) in the
presence of polyvinylpyrrolidone and cured at a moderate
temperature of about 50.degree. C.
[0245] In some preferred embodiments, the electrode domain 56 is
formed from a hydrophilic polymer such as polyvinylpyrrolidone
(PVP). An electrode domain formed from PVP has been shown to reduce
break-in time of analyte sensors; for example, a glucose sensor
utilizing a cellulosic-based interference domain such as described
in more detail below.
[0246] In one embodiment, the electrode domain 56 is formed from a
silicone polymer/hydrophobic-hydrophilic polymer blend. In one
embodiment, The hydrophobic-hydrophilic polymer for use in the
blend may be any suitable hydrophobic-hydrophilic polymer,
including but not limited to components such as
polyvinylpyrrolidone (PVP), polyhydroxyethyl methacrylate,
polyvinylalcohol, polyacrylic acid, polyethers such as polyethylene
glycol or polypropylene oxide, and copolymers thereof, including,
for example, di-block, tri-block, alternating, random, comb, star,
dendritic, and graft copolymers (block copolymers are discussed in
U.S. Pat. Nos. 4,803,243 and 4,686,044, which are incorporated
herein by reference). In one embodiment, the
hydrophobic-hydrophilic polymer is a copolymer of poly(ethylene
oxide) (PEO) and poly(propylene oxide) (PPO). Suitable such
polymers include, but are not limited to, PEO-PPO diblock
copolymers, PPO-PEO-PPO triblock copolymers, PEO-PPO-PEO triblock
copolymers, alternating block copolymers of PEO-PPO, random
copolymers of ethylene oxide and propylene oxide, and blends
thereof. In some embodiments, the copolymers may be optionally
substituted with hydroxy substituents. Commercially available
examples of PEO and PPO copolymers include the PLURONIC.RTM. brand
of polymers available from BASF.RTM.. In one embodiment,
PLURONIC.RTM. F-127 is used. Other PLURONIC.RTM. polymers include
PPO-PEO-PPO triblock copolymers (e.g., PLURONIC.RTM. R products).
Other suitable commercial polymers include, but are not limited to,
SYNPERONICS.RTM. products available from UNIQEMA.RTM..
[0247] The silicone polymer for use in the
silicone/hydrophobic-hydrophilic polymer blend may be any suitable
silicone polymer. In some embodiments, the silicone polymer is a
liquid silicone rubber that may be vulcanized using a metal- (e.g.,
platinum), peroxide-, heat-, ultraviolet-, or other
radiation-catalyzed process. In some embodiments, the silicone
polymer is a dimethyl- and methylhydrogen-siloxane copolymer. In
some embodiments, the copolymer has vinyl substituents. In some
embodiments, commercially available silicone polymers may be used.
For example, commercially available silicone polymer precursor
compositions may be used to prepare the blends, such as described
below. In one embodiment, MED-4840 available from NUSIL.RTM.
Technology LLC is used as a precursor to the silicone polymer used
in the blend. MED-4840 consists of a 2-part silicone elastomer
precursor including vinyl-functionalized dimethyl- and
methylhydrogen-siloxane copolymers, amorphous silica, a platinum
catalyst, a crosslinker, and an inhibitor. The two components may
be mixed together and heated to initiate vulcanization, thereby
forming an elastomeric solid material. Other suitable silicone
polymer precursor systems include, but are not limited to, MED-2174
peroxide-cured liquid silicone rubber available from NUSIL.RTM.
Technology LLC, SILASTIC.RTM. MDX4-4210 platinum-cured biomedical
grade elastomer available from DOW CORNING.RTM., and Implant Grade
Liquid Silicone Polymer (durometers 10-50) available from Applied
Silicone Corporation.
[0248] Silicone polymer/hydrophobic-hydrophilic polymer blends are
described in more detail in U.S. patent application Ser. No.
11/404,417, entitled "SILICONE BASED MEMBRANES FOR USE IN
IMPLANTABLE GLUCOSE SENSORS," filed on Apr. 14, 2006, which is
incorporated herein by reference in its entirety.
[0249] Preferably, the electrode domain is deposited by vapor
deposition, spray coating, dip coating, casting, or other thin film
techniques on the electroactive surfaces of the sensor. In one
preferred embodiment, the electrode domain is formed by dip-coating
the electroactive surfaces in an electrode domain solution and
curing the domain for a time of from about 15 minutes to about 30
minutes at a temperature of from about 40.degree. C. to about
55.degree. C. (and can be accomplished under vacuum (e.g., 20 to 30
mmHg)). In embodiments wherein dip-coating is used to deposit the
electrode domain, a preferred insertion rate of from about 1 to
about 3 inches per minute into the electrolyte layer solution, with
a preferred dwell time of from about 0.5 to about 2 minutes in the
electrolyte layer solution, and a preferred withdrawal rate of from
about 0.25 to about 2 inches per minute from the electrolyte layer
solution provide a functional coating. However, values outside of
those set forth above can be acceptable or even desirable in
certain embodiments, for example, depending upon solution viscosity
and solution surface tension, as is appreciated by one skilled in
the art. In one embodiment, the electroactive surfaces of the
electrode system are dip-coated one time (one layer) and cured at
50.degree. C. under vacuum for 20 minutes.
[0250] Although an independent electrode domain 56 is described
herein, in some embodiments sufficient hydrophilicity can be
provided in the interference domain and/or enzyme domain (the
domain adjacent to the electroactive surfaces) so as to provide for
the full transport of ions in the aqueous environment (e.g. without
a distinct electrode domain). In these embodiments, an electrode
domain is not necessary.
[0251] Interference Domain
[0252] Interferents are molecules or other species that are reduced
or oxidized at the electrochemically reactive surfaces of the
sensor, either directly or via an electron transfer agent, to
produce a false positive analyte signal. In preferred embodiments,
an interference domain 57 is provided that substantially restricts,
resists, or blocks the flow of one or more interfering species.
Some known interfering species for a glucose sensor, as described
in more detail above, include acetaminophen, ascorbic acid,
bilirubin, cholesterol, creatinine, dopamine, ephedrine, ibuprofen,
L-dopa, methyl dopa, salicylate, tetracycline, tolazamide,
tolbutamide, triglycerides, and uric acid. In general, the
interference domain of the preferred embodiments is less permeable
to one or more of the interfering species than to the analyte,
e.g., glucose.
[0253] In some embodiments, the interference domain 57 is formed
from one or more cellulosic derivatives. In general, cellulosic
derivatives include polymers such as cellulose acetate, cellulose
acetate butyrate, 2-hydroxyethyl cellulose, cellulose acetate
phthalate, cellulose acetate propionate, cellulose acetate
trimellitate, and the like.
[0254] In one embodiment, the interference domain 57 is formed from
cellulose acetate butyrate. Cellulose acetate butyrate with a
molecular weight of about 10,000 daltons to about 75,000 daltons,
preferably from about 15,000, 20,000, or 25,000 daltons to about
50,000, 55,000, 60,000, 65,000, or 70,000 daltons, and more
preferably about 20,000 daltons is employed. In certain
embodiments, however, higher or lower molecular weights can be
preferred. Additionally, a casting solution or dispersion of
cellulose acetate butyrate at a weight percent of about 15% to
about 25%, preferably from about 15%, 16%, 17%, 18%, 19% to about
20%, 21%, 22%, 23%, 24% or 25%, and more preferably about 18% is
preferred. Preferably, the casting solution includes a solvent or
solvent system, for example an acetone:ethanol solvent system.
Higher or lower concentrations can be preferred in certain
embodiments. A plurality of layers of cellulose acetate butyrate
can be advantageously combined to form the interference domain in
some embodiments, for example, three layers can be employed. It can
be desirable to employ a mixture of cellulose acetate butyrate
components with different molecular weights in a single solution,
or to deposit multiple layers of cellulose acetate butyrate from
different solutions comprising cellulose acetate butyrate of
different molecular weights, different concentrations, and/or
different chemistries (e.g., functional groups). It can also be
desirable to include additional substances in the casting solutions
or dispersions, e.g., functionalizing agents, crosslinking agents,
other polymeric substances, substances capable of modifying the
hydrophilicity/hydrophobicity of the resulting layer, and the
like.
[0255] In one alternative embodiment, the interference domain 57 is
formed from cellulose acetate. Cellulose acetate with a molecular
weight of about 30,000 daltons or less to about 100,000 daltons or
more, preferably from about 35,000, 40,000, or 45,000 daltons to
about 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000,
90,000, or 95,000 daltons, and more preferably about 50,000 daltons
is preferred. Additionally, a casting solution or dispersion of
cellulose acetate at a weight percent of about 3% to about 10%,
preferably from about 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, or 6.5%
to about 7.5%, 8.0%, 8.5%, 9.0%, or 9.5%, and more preferably about
8% is preferred. In certain embodiments, however, higher or lower
molecular weights and/or cellulose acetate weight percentages can
be preferred. It can be desirable to employ a mixture of cellulose
acetates with molecular weights in a single solution, or to deposit
multiple layers of cellulose acetate from different solutions
comprising cellulose acetates of different molecular weights,
different concentrations, or different chemistries (e.g.,
functional groups). It can also be desirable to include additional
substances in the casting solutions or dispersions such as
described in more detail above.
[0256] Layer(s) prepared from combinations of cellulose acetate and
cellulose acetate butyrate, or combinations of layer(s) of
cellulose acetate and layer(s) of cellulose acetate butyrate can
also be employed to form the interference domain 57.
[0257] In some alternative embodiments, additional polymers, such
as Nafion.RTM., can be used in combination with cellulosic
derivatives to provide equivalent and/or enhanced function of the
interference domain 57. As one example, a 5 wt % Nafion.RTM.
casting solution or dispersion can be used in combination with a 8
wt % cellulose acetate casting solution or dispersion, e.g., by dip
coating at least one layer of cellulose acetate and subsequently
dip coating at least one layer Nafion.RTM. onto a sensor such as
described with reference to the preferred embodiments. Any number
of coatings or layers formed in any order may be suitable for
forming the interference domain of the preferred embodiments.
[0258] In some alternative embodiments, more than one cellulosic
derivative can be used to form the interference domain 57 of the
preferred embodiments. In general, the formation of the
interference domain on a surface utilizes a solvent or solvent
system in order to solvate the cellulosic derivative (or other
polymer) prior to film formation thereon. In preferred embodiments,
acetone and ethanol are used as solvents for cellulose acetate;
however one skilled in the art appreciates the numerous solvents
that are suitable for use with cellulosic derivatives (and other
polymers). Additionally, one skilled in the art appreciates that
the preferred relative amounts of solvent can be dependent upon the
cellulosic derivative (or other polymer) used, its molecular
weight, its method of deposition, its desired thickness, and the
like. However, a percent solute of from about 1% to about 25% is
preferably used to form the interference domain solution so as to
yield an interference domain having the desired properties. The
cellulosic derivative (or other polymer) used, its molecular
weight, method of deposition, and desired thickness can be
adjusted, depending upon one or more other of the parameters, and
can be varied accordingly as is appreciated by one skilled in the
art.
[0259] In some alternative embodiments, other polymer types that
can be utilized as a base material for the interference domain 57
including polyurethanes, polymers having pendant ionic groups, and
polymers having controlled pore size, for example. In one such
alternative embodiment, the interference domain includes a thin,
hydrophobic membrane that is non-swellable and restricts diffusion
of low molecular weight species. The interference domain 57 is
permeable to relatively low molecular weight substances, such as
hydrogen peroxide, but restricts the passage of higher molecular
weight substances, including glucose and ascorbic acid. Other
systems and methods for reducing or eliminating interference
species that can be applied to the membrane system of the preferred
embodiments are described in U.S. Publication No.
US-2005-0115832-A1, U.S. Publication No. US-2005-0176136-A1, U.S.
Publication No. US-2005-0161346-A1, and U.S. Publication No.
US-2005-0143635-A1. In some alternative embodiments, a distinct
interference domain is not included (e.g., wherein interferants are
resisted by other domains and/or wherein the sensing mechanism does
not have interferants).
[0260] In one embodiment, the interference domain 57 is formed from
a silicone polymer/hydrophobic-hydrophilic polymer blend. In one
embodiment, The hydrophobic-hydrophilic polymer for use in the
blend may be any suitable hydrophobic-hydrophilic polymer,
including but not limited to components such as
polyvinylpyrrolidone (PVP), polyhydroxyethyl methacrylate,
polyvinylalcohol, polyacrylic acid, polyethers such as polyethylene
glycol or polypropylene oxide, and copolymers thereof, including,
for example, di-block, tri-block, alternating, random, comb, star,
dendritic, and graft copolymers (block copolymers are discussed in
U.S. Pat. Nos. 4,803,243 and 4,686,044, which are incorporated
herein by reference). In one embodiment, the
hydrophobic-hydrophilic polymer is a copolymer of poly(ethylene
oxide) (PEO) and poly(propylene oxide) (PPO). Suitable such
polymers include, but are not limited to, PEO-PPO diblock
copolymers, PPO-PEO-PPO triblock copolymers, PEO-PPO-PEO triblock
copolymers, alternating block copolymers of PEO-PPO, random
copolymers of ethylene oxide and propylene oxide, and blends
thereof. In some embodiments, the copolymers may be optionally
substituted with hydroxy substituents. Commercially available
examples of PEO and PPO copolymers include the PLURONIC.RTM. brand
of polymers available from BASF.RTM.. In one embodiment,
PLURONIC.RTM. F-127 is used. Other PLURONIC.RTM. polymers include
PPO-PEO-PPO triblock copolymers (e.g., PLURONIC.RTM. R products).
Other suitable commercial polymers include, but are not limited to,
SYNPERONICS.RTM. products available from UNIQEMA.RTM..
[0261] The silicone polymer for use in the
silicone/hydrophobic-hydrophilic polymer blend may be any suitable
silicone polymer. In some embodiments, the silicone polymer is a
liquid silicone rubber that may be vulcanized using a metal- (e.g.,
platinum), peroxide-, heat-, ultraviolet-, or other
radiation-catalyzed process. In some embodiments, the silicone
polymer is a dimethyl- and methylhydrogen-siloxane copolymer. In
some embodiments, the copolymer has vinyl substituents. In some
embodiments, commercially available silicone polymers may be used.
For example, commercially available silicone polymer precursor
compositions may be used to prepare the blends, such as described
below. In one embodiment, MED-4840 available from NUSIL.RTM.
Technology LLC is used as a precursor to the silicone polymer used
in the blend. MED-4840 consists of a 2-part silicone elastomer
precursor including vinyl-functionalized dimethyl- and
methylhydrogen-siloxane copolymers, amorphous silica, a platinum
catalyst, a crosslinker, and an inhibitor. The two components may
be mixed together and heated to initiate vulcanization, thereby
forming an elastomeric solid material. Other suitable silicone
polymer precursor systems include, but are not limited to, MED-2174
peroxide-cured liquid silicone rubber available from NUSIL.RTM.
Technology LLC, SILASTIC.RTM. MDX4-4210 platinum-cured biomedical
grade elastomer available from DOW CORNING.RTM., and Implant Grade
Liquid Silicone Polymer (durometers 10-50) available from Applied
Silicone Corporation.
[0262] Silicone polymer/hydrophobic-hydrophilic polymer blends are
described in more detail in U.S. patent application Ser. No.
11/404,417, entitled "SILICONE BASED MEMBRANES FOR USE IN
IMPLANTABLE GLUCOSE SENSORS," filed on Apr. 14, 2006, which is
incorporated herein by reference in its entirety.
[0263] In preferred embodiments, the interference domain 57 is
deposited directly onto the electroactive surfaces of the sensor
for a domain thickness of from about 0.05 micron or less to about
20 microns or more, more preferably from about 0.05, 0.1, 0.15,
0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5
microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, or 19.5 microns, and more preferably still from about 1,
1.5 or 2 microns to about 2.5 or 3 microns. Thicker membranes can
also be desirable in certain embodiments, but thinner membranes are
generally preferred because they have a lower impact on the rate of
diffusion of hydrogen peroxide from the enzyme membrane to the
electrodes.
[0264] In general, the membrane systems of the preferred
embodiments can be formed and/or deposited on the exposed
electroactive surfaces (e.g., one or more of the working and
reference electrodes) using known thin film techniques (for
example, casting, spray coating, drawing down, electro-depositing,
dip coating, and the like), however casting or other known
application techniques can also be utilized. Preferably, the
interference domain is deposited by vapor deposition, spray
coating, or dip coating. In one exemplary embodiment, the
interference domain is formed by dip coating the sensor into an
interference domain solution using an insertion rate of from about
20 inches/min to about 60 inches/min, preferably 40 inches/min, a
dwell time of from about 0 minute to about 5 seconds, preferably 0
seconds, and a withdrawal rate of from about 20 inches/minute to
about 60 inches/minute, preferably about 40 inches/minute, and
curing (drying) the domain from about 1 minute to about 30 minutes,
preferably from about 3 minutes to about 15 minutes (and can be
accomplished at room temperature or under vacuum (e.g., 20 to 30
mmHg)). In one exemplary embodiment including cellulose acetate
butyrate interference domain, a 3-minute cure (i.e., dry) time is
preferred between each layer applied. In another exemplary
embodiment employing a cellulose acetate interference domain, a 15
minute cure (i.e., dry) time is preferred between each layer
applied.
[0265] The dip process can be repeated at least one time and up to
10 times or more. The preferred number of repeated dip processes
depends upon the cellulosic derivative(s) used, their
concentration, conditions during deposition (e.g., dipping) and the
desired thickness (e.g., sufficient thickness to provide functional
blocking of (or resistance to) certain interferents), and the like.
In some embodiments, 1 to 3 microns may be preferred for the
interference domain thickness; however, values outside of these can
be acceptable or even desirable in certain embodiments, for
example, depending upon viscosity and surface tension, as is
appreciated by one skilled in the art. In one exemplary embodiment,
an interference domain is formed from three layers of cellulose
acetate butyrate. In another exemplary embodiment, an interference
domain is formed from 10 layers of cellulose acetate. In
alternative embodiments, the interference domain can be formed
using any known method and combination of cellulose acetate and
cellulose acetate butyrate, as will be appreciated by one skilled
in the art.
[0266] In some embodiments, the electroactive surface can be
cleaned prior to application of the interference domain 57. In some
embodiments, the interference domain 57 of the preferred
embodiments can be useful as a bioprotective or biocompatible
domain, namely, a domain that interfaces with host tissue when
implanted in an animal (e.g., a human) due to its stability and
biocompatibility.
[0267] Enzyme Domain
[0268] In preferred embodiments, the membrane system further
includes an enzyme domain 58 disposed more distally from the
electroactive surfaces than the interference domain 57; however
other configurations can be desirable. In the preferred
embodiments, the enzyme domain provides an enzyme to catalyze the
reaction of the analyte and its co-reactant. In the preferred
embodiments of a glucose sensor, the enzyme domain includes glucose
oxidase; however other oxidases, for example, galactose oxidase or
uricase oxidase, can also be used.
[0269] For an enzyme-based electrochemical glucose sensor to
perform well, the sensor's response is preferably limited by
neither enzyme activity nor co-reactant concentration. Because
enzymes, including glucose oxidase, are subject to deactivation as
a function of time even in ambient conditions, this behavior is
compensated for in forming the enzyme domain. Preferably, the
enzyme domain is constructed of aqueous dispersions of colloidal
polyurethane polymers including the enzyme. However, in alternative
embodiments the enzyme domain is constructed from an oxygen
enhancing material, for example, silicone, or fluorocarbon.
Preferably, the enzyme is immobilized within the domain. See, e.g.,
U.S. patent application Ser. No. 10/896,639 filed on Jul. 21, 2004
and entitled "Oxygen Enhancing Membrane Systems for Implantable
Device."
[0270] In one embodiment, the enzyme domain 58 is formed from a
silicone polymer/hydrophobic-hydrophilic polymer blend. In one
embodiment, The hydrophobic-hydrophilic polymer for use in the
blend may be any suitable hydrophobic-hydrophilic polymer,
including but not limited to components such as
polyvinylpyrrolidone (PVP), polyhydroxyethyl methacrylate,
polyvinylalcohol, polyacrylic acid, polyethers such as polyethylene
glycol or polypropylene oxide, and copolymers thereof, including,
for example, di-block, tri-block, alternating, random, comb, star,
dendritic, and graft copolymers (block copolymers are discussed in
U.S. Pat. Nos. 4,803,243 and 4,686,044, which are incorporated
herein by reference). In one embodiment, the
hydrophobic-hydrophilic polymer is a copolymer of poly(ethylene
oxide) (PEO) and poly(propylene oxide) (PPO). Suitable such
polymers include, but are not limited to, PEO-PPO diblock
copolymers, PPO-PEO-PPO triblock copolymers, PEO-PPO-PEO triblock
copolymers, alternating block copolymers of PEO-PPO, random
copolymers of ethylene oxide and propylene oxide, and blends
thereof. In some embodiments, the copolymers may be optionally
substituted with hydroxy substituents. Commercially available
examples of PEO and PPO copolymers include the PLURONIC.RTM. brand
of polymers available from BASF.RTM.. In one embodiment,
PLURONIC.RTM. F-127 is used. Other PLURONIC.RTM. polymers include
PPO-PEO-PPO triblock copolymers (e.g., PLURONIC.RTM. R products).
Other suitable commercial polymers include, but are not limited to,
SYNPERONICS.RTM. products available from UNIQEMA.RTM..
[0271] The silicone polymer for use in the
silicone/hydrophobic-hydrophilic polymer blend may be any suitable
silicone polymer. In some embodiments, the silicone polymer is a
liquid silicone rubber that may be vulcanized using a metal- (e.g.,
platinum), peroxide-, heat-, ultraviolet-, or other
radiation-catalyzed process. In some embodiments, the silicone
polymer is a dimethyl- and methylhydrogen-siloxane copolymer. In
some embodiments, the copolymer has vinyl substituents. In some
embodiments, commercially available silicone polymers may be used.
For example, commercially available silicone polymer precursor
compositions may be used to prepare the blends, such as described
below. In one embodiment, MED-4840 available from NUSIL.RTM.
Technology LLC is used as a precursor to the silicone polymer used
in the blend. MED-4840 consists of a 2-part silicone elastomer
precursor including vinyl-functionalized dimethyl- and
methylhydrogen-siloxane copolymers, amorphous silica, a platinum
catalyst, a crosslinker, and an inhibitor. The two components may
be mixed together and heated to initiate vulcanization, thereby
forming an elastomeric solid material. Other suitable silicone
polymer precursor systems include, but are not limited to, MED-2174
peroxide-cured liquid silicone rubber available from NUSIL.RTM.
Technology LLC, SILASTIC.RTM. MDX4-4210 platinum-cured biomedical
grade elastomer available from DOW CORNING.RTM., and Implant Grade
Liquid Silicone Polymer (durometers 10-50) available from Applied
Silicone Corporation.
[0272] Silicone polymer/hydrophobic-hydrophilic polymer blends are
described in more detail in U.S. patent application Ser. No.
11/404,417, entitled "SILICONE BASED MEMBRANES FOR USE IN
IMPLANTABLE GLUCOSE SENSORS," filed on Apr. 14, 2006, which is
incorporated herein by reference in its entirety.
[0273] In preferred embodiments, the enzyme domain is deposited
onto the interference domain for a domain thickness of from about
0.05 micron or less to about 20 microns or more, more preferably
from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5,
1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, and more
preferably still from about 2, 2.5 or 3 microns to about 3.5, 4,
4.5, or 5 microns. However in some embodiments, the enzyme domain
can be deposited directly onto the electroactive surfaces.
Preferably, the enzyme domain is deposited by spray or dip coating.
In one embodiment, the enzyme domain is formed by dip coating the
interference domain coated sensor into an enzyme domain solution
and curing the domain for from about 15 to about 30 minutes at a
temperature of from about 40.degree. C. to about 55.degree. C. (and
can be accomplished under vacuum (e.g., 20 to 30 mmHg)). In
embodiments wherein dip coating is used to deposit the enzyme
domain at room temperature, a preferred insertion rate of from
about 0.25 inch per minute to about 3 inches per minute, with a
preferred dwell time of from about 0.5 minutes to about 2 minutes,
and a preferred withdrawal rate of from about 0.25 inch per minute
to about 2 inches per minute provides a functional coating.
However, values outside of those set forth above can be acceptable
or even desirable in certain embodiments, for example, depending
upon viscosity and surface tension, as is appreciated by one
skilled in the art. In one embodiment, the enzyme domain is formed
by dip coating two times (namely, forming two layers) in an enzyme
domain solution and curing at 50.degree. C. under vacuum for 20
minutes. However, in some embodiments, the enzyme domain can be
formed by dip coating and/or spray coating one or more layers at a
predetermined concentration of the coating solution, insertion
rate, dwell time, withdrawal rate, and/or desired thickness.
[0274] Resistance Domain
[0275] In preferred embodiments, the membrane system includes a
resistance domain 59 disposed more distal from the electroactive
surfaces than the enzyme domain. Although the following description
is directed to a resistance domain for a glucose sensor, the
resistance domain can be modified for other analytes and
co-reactants as well.
[0276] There exists a molar excess of glucose relative to the
amount of oxygen in blood; that is, for every free oxygen molecule
in extracellular fluid, there are typically more than 100 glucose
molecules present (see Updike et al., Diabetes Care
5:207-21(1982)). However, an immobilized enzyme-based glucose
sensor employing oxygen as co-reactant is preferably supplied with
oxygen in non-rate-limiting excess in order for the sensor to
respond linearly to changes in glucose concentration, while not
responding to changes in oxygen concentration. Specifically, when a
glucose-monitoring reaction is oxygen limited, linearity is not
achieved above minimal concentrations of glucose. Without a
semipermeable membrane situated over the enzyme domain to control
the flux of glucose and oxygen, a linear response to glucose levels
can be obtained only for glucose concentrations of up to about 40
mg/dL. However, in a clinical setting, a linear response to glucose
levels is desirable up to at least about 400 mg/dL.
[0277] The resistance domain includes a semipermeable membrane that
controls the flux of oxygen and glucose to the underlying enzyme
domain, preferably rendering oxygen in a non-rate-limiting excess.
As a result, the upper limit of linearity of glucose measurement is
extended to a much higher value than that which is achieved without
the resistance domain. In one embodiment, the resistance domain
exhibits an oxygen to glucose permeability ratio of from about 50:1
or less to about 400:1 or more, preferably about 200:1. As a
result, one-dimensional reactant diffusion is adequate to provide
excess oxygen at all reasonable glucose and oxygen concentrations
found in the subcutaneous matrix (See Rhodes et al., Anal. Chem.,
66:1520-1529 (1994)).
[0278] In alternative embodiments, a lower ratio of
oxygen-to-glucose can be sufficient to provide excess oxygen by
using a high oxygen solubility domain (for example, a silicone or
fluorocarbon-based material or domain) to enhance the
supply/transport of oxygen to the enzyme domain. If more oxygen is
supplied to the enzyme, then more glucose can also be supplied to
the enzyme without creating an oxygen rate-limiting excess. In
alternative embodiments, the resistance domain is formed from a
silicone composition, such as is described in U.S. Publication No.
US-2005-0090607-A1.
[0279] In a preferred embodiment, the resistance domain includes a
polyurethane membrane with both hydrophilic and hydrophobic regions
to control the diffusion of glucose and oxygen to an analyte
sensor, the membrane being fabricated easily and reproducibly from
commercially available materials. A suitable hydrophobic polymer
component is a polyurethane, or polyetherurethaneurea. Polyurethane
is a polymer produced by the condensation reaction of a
diisocyanate and a difunctional hydroxyl-containing material. A
polyurethaneurea is a polymer produced by the condensation reaction
of a diisocyanate and a difunctional amine-containing material.
Preferred diisocyanates include aliphatic diisocyanates containing
from about 4 to about 8 methylene units. Diisocyanates containing
cycloaliphatic moieties can also be useful in the preparation of
the polymer and copolymer components of the membranes of preferred
embodiments. The material that forms the basis of the hydrophobic
matrix of the resistance domain can be any of those known in the
art as appropriate for use as membranes in sensor devices and as
having sufficient permeability to allow relevant compounds to pass
through it, for example, to allow an oxygen molecule to pass
through the membrane from the sample under examination in order to
reach the active enzyme or electrochemical electrodes. Examples of
materials which can be used to make non-polyurethane type membranes
include vinyl polymers, polyethers, polyesters, polyamides,
inorganic polymers such as polysiloxanes and polycarbosiloxanes,
natural polymers such as cellulosic and protein based materials,
and mixtures or combinations thereof.
[0280] In a preferred embodiment, the hydrophilic polymer component
is polyethylene oxide. For example, one useful
hydrophobic-hydrophilic copolymer component is a polyurethane
polymer that includes about 20% hydrophilic polyethylene oxide. The
polyethylene oxide portions of the copolymer are thermodynamically
driven to separate from the hydrophobic portions of the copolymer
and the hydrophobic polymer component. The 20% polyethylene
oxide-based soft segment portion of the copolymer used to form the
final blend affects the water pick-up and subsequent glucose
permeability of the membrane.
[0281] In one preferred embodiment, the resistance domain 59 is
formed from a silicone polymer/hydrophobic-hydrophilic polymer
blend. In one embodiment, The hydrophobic-hydrophilic polymer for
use in the blend may be any suitable hydrophobic-hydrophilic
polymer, including but not limited to components such as
polyvinylpyrrolidone (PVP), polyhydroxyethyl methacrylate,
polyvinylalcohol, polyacrylic acid, polyethers such as polyethylene
glycol or polypropylene oxide, and copolymers thereof, including,
for example, di-block, tri-block, alternating, random, comb, star,
dendritic, and graft copolymers (block copolymers are discussed in
U.S. Pat. Nos. 4,803,243 and 4,686,044, which are incorporated
herein by reference). In one embodiment, the
hydrophobic-hydrophilic polymer is a copolymer of poly(ethylene
oxide) (PEO) and poly(propylene oxide) (PPO). Suitable such
polymers include, but are not limited to, PEO-PPO diblock
copolymers, PPO-PEO-PPO triblock copolymers, PEO-PPO-PEO triblock
copolymers, alternating block copolymers of PEO-PPO, random
copolymers of ethylene oxide and propylene oxide, and blends
thereof. In some embodiments, the copolymers may be optionally
substituted with hydroxy substituents. Commercially available
examples of PEO and PPO copolymers include the PLURONIC.RTM. brand
of polymers available from BASF.RTM.. In one embodiment,
PLURONIC.RTM. F-127 is used. Other PLURONIC.RTM. polymers include
PPO-PEO-PPO triblock copolymers (e.g., PLURONIC.RTM. R products).
Other suitable commercial polymers include, but are not limited to,
SYNPERONICS.RTM. products available from UNIQEMA.RTM..
[0282] The silicone polymer for use in the
silicone/hydrophobic-hydrophilic polymer blend may be any suitable
silicone polymer. In some embodiments, the silicone polymer is a
liquid silicone rubber that may be vulcanized using a metal- (e.g.,
platinum), peroxide-, heat-, ultraviolet-, or other
radiation-catalyzed process. In some embodiments, the silicone
polymer is a dimethyl- and methylhydrogen-siloxane copolymer. In
some embodiments, the copolymer has vinyl substituents. In some
embodiments, commercially available silicone polymers may be used.
For example, commercially available silicone polymer precursor
compositions may be used to prepare the blends, such as described
below. In one embodiment, MED-4840 available from NUSIL.RTM.
Technology LLC is used as a precursor to the silicone polymer used
in the blend. MED-4840 consists of a 2-part silicone elastomer
precursor including vinyl-functionalized dimethyl- and
methylhydrogen-siloxane copolymers, amorphous silica, a platinum
catalyst, a crosslinker, and an inhibitor. The two components may
be mixed together and heated to initiate vulcanization, thereby
forming an elastomeric solid material. Other suitable silicone
polymer precursor systems include, but are not limited to, MED-2174
peroxide-cured liquid silicone rubber available from NUSIL.RTM.
Technology LLC, SILASTIC.RTM. MDX4-4210 platinum-cured biomedical
grade elastomer available from DOW CORNING.RTM., and Implant Grade
Liquid Silicone Polymer (durometers 10-50) available from Applied
Silicone Corporation.
[0283] Silicone polymer/hydrophobic-hydrophilic polymer blends are
described in more detail in U.S. patent application Ser. No.
11/404,417, entitled "SILICONE BASED MEMBRANES FOR USE IN
IMPLANTABLE GLUCOSE SENSORS," filed on Apr. 14, 2006, which is
incorporated herein by reference in its entirety.
[0284] In preferred embodiments, the resistance domain is deposited
onto the enzyme domain to yield a domain thickness of from about
0.05 microns or less to about 20 microns or more, more preferably
from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5,
1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, and more
preferably still from about 2, 2.5 or 3 microns to about 3.5, 4,
4.5, or 5 microns. Preferably, the resistance domain is deposited
onto the enzyme domain by vapor deposition, spray coating, or dip
coating. In one preferred embodiment, spray coating is the
preferred deposition technique. The spraying process atomizes and
mists the solution, and therefore most or all of the solvent is
evaporated prior to the coating material settling on the underlying
domain, thereby minimizing contact of the solvent with the
enzyme.
[0285] In another preferred embodiment, physical vapor deposition
(e.g., ultrasonic vapor deposition) is used for coating one or more
of the membrane domain(s) onto the electrodes, wherein the vapor
deposition apparatus and process include an ultrasonic nozzle that
produces a mist of micro-droplets in a vacuum chamber. In these
embodiments, the micro-droplets move turbulently within the vacuum
chamber, isotropically impacting and adhering to the surface of the
substrate. Advantageously, vapor deposition as described above can
be implemented to provide high production throughput of membrane
deposition processes (e.g., at least about 20 to about 200 or more
electrodes per chamber), greater consistency of the membrane on
each sensor, and increased uniformity of sensor performance, for
example, as described below.
[0286] In some embodiments, depositing the resistance domain (for
example, as described in the preferred embodiments above) includes
formation of a membrane system that substantially blocks or resists
ascorbate (a known electrochemical interferant in hydrogen
peroxide-measuring glucose sensors). While not wishing to be bound
by theory, it is believed that during the process of depositing the
resistance domain as described in the preferred embodiments, a
structural morphology is formed that is characterized in that
ascorbate does not substantially permeate therethrough.
[0287] In a preferred embodiment, the resistance domain is
deposited on the enzyme domain by spray coating a solution of from
about 1 wt. % to about 5 wt. % polymer and from about 95 wt. % to
about 99 wt. % solvent. In spraying a solution of resistance domain
material, including a solvent, onto the enzyme domain, it is
desirable to mitigate or substantially reduce any contact with
enzyme of any solvent in the spray solution that can deactivate the
underlying enzyme of the enzyme domain. Tetrahydrofuran (THF) is
one solvent that minimally or negligibly affects the enzyme of the
enzyme domain upon spraying. Other solvents can also be suitable
for use, as is appreciated by one skilled in the art.
[0288] Although a variety of spraying or deposition techniques can
be used, spraying the resistance domain material and rotating the
sensor at least one time by 180.degree. can typically provide
adequate coverage by the resistance domain. Spraying the resistance
domain material and rotating the sensor at least two times by
120.degree. provides even greater coverage (one layer of
360.degree. coverage), thereby ensuring resistivity to glucose,
such as is described in more detail above.
[0289] In preferred embodiments, the resistance domain is spray
coated and subsequently cured for a time of from about 15 minutes
to about 90 minutes at a temperature of from about 40.degree. C. to
about 60.degree. C. (and can be accomplished under vacuum (e.g.,
from 20 to 30 mmHg)). A cure time of up to about 90 minutes or more
can be advantageous to ensure complete drying of the resistance
domain.
[0290] In one embodiment, the resistance domain is formed by spray
coating at least six layers (namely, rotating the sensor seventeen
times by 120.degree. for at least six layers of 360.degree.
coverage) and curing at 50.degree. C. under vacuum for 60 minutes.
However, the resistance domain can be formed by dip coating or
spray coating any layer or plurality of layers, depending upon the
concentration of the solution, insertion rate, dwell time,
withdrawal rate, and/or the desired thickness of the resulting
film. Additionally, curing in a convention oven can also be
employed.
[0291] In certain embodiments, a variable frequency microwave oven
can be used to cure the membrane domains/layers. In general,
microwave ovens directly excite the rotational mode of solvents.
Consequently, microwave ovens cure coatings from the inside out
rather than from the outside in as with conventional convection
ovens. This direct rotational mode excitation is responsible for
the typically observed "fast" curing within a microwave oven. In
contrast to conventional microwave ovens, which rely upon a fixed
frequency of emission that can cause arcing of dielectric
(metallic) substrates if placed within a conventional microwave
oven, Variable Frequency Microwave (VFM) ovens emit thousands of
frequencies within 100 milliseconds, which substantially eliminates
arcing of dielectric substrates. Consequently, the membrane
domains/layers can be cured even after deposition on metallic
electrodes as described herein. While not wishing to be bound by
theory, it is believe that VFM curing can increase the rate and
completeness of solvent evaporation from a liquid membrane solution
applied to a sensor, as compared to the rate and completeness of
solvent evaporation observed for curing in conventional convection
ovens.
[0292] In certain embodiments, VFM is can be used together with
convection oven curing to further accelerate cure time. In some
sensor applications wherein the membrane is cured prior to
application on the electrode (see, for example, U.S. Publication
No. US-2005-0245799-A1, which is incorporated herein by reference
in its entirety), conventional microwave ovens (e.g., fixed
frequency microwave ovens) can be used to cure the membrane
layer.
[0293] Bioprotective Domain
[0294] The bioprotective domain, if present, is positioned less
distal to the implantable device than the cell disruptive layer,
and can be resistant to cellular attachment, impermeable to cells,
and/or is composed of a biostable material. When the bioprotective
domain is resistant to cellular attachment (for example, attachment
by inflammatory cells, such as macrophages, which are therefore
kept a sufficient distance from other domains, for example, the
enzyme domain), hypochlorite and other oxidizing species are
short-lived chemical species in vivo, and biodegradation does not
occur. Additionally, the materials preferred for forming the
bioprotective domain may be resistant to the effects of these
oxidative species and have thus been termed biodurable. See, for
example, U.S. Pat. No. 6,702,857, filed Jul. 27, 2001, and entitled
"MEMBRANE FOR USE WITH IMPLANTABLE DEVICES" and U.S. patent
application Ser. No. 10/647,065, filed Aug. 22, 2003, published in
Publication No. 20050112169 and entitled, "POROUS MEMBRANES FOR USE
WITH IMPLANTABLE DEVICES," both of which are incorporated herein by
reference in their entirety.
[0295] In one embodiment, bioprotective domain is formed from high
oxygen soluble materials such as polymers formed from silicone,
fluorocarbons, perfluorocarbons, or the like. In one embodiment,
the cell impermeable domain is formed from a silicone composition
with a hydrophile such as such as polyethylene glycol, propylene
glycol, pyrrolidone, esters, amides, carbonates, or polypropylene
glycol covalently incorporated or grafted therein. In still other
embodiments, the bioprotective domain is formed from a monomer,
polymer, copolymer, or blend including one or more of: lactic acid,
glycolic acid, anhydrides, phospazenes, vinyl alcohol, ethylene
vinyl alcohol, acetates, .epsilon.-caprolactone,
.beta.-hydroxybutyrate, .gamma.-ethyl glutamate, DTH
iminocarbonate, Bisphenol A iminocarbonate, sebacic acid,
hexadecanoic acid, saccharides, chitosan, hydyoxyethyl methacrylate
(HEMA), ceramics, hyaluronic acid (HA), collagen, gelatin,
starches, hydroxy apatite, calcium phosphates, bioglasses, amino
acid sequences, proteins, glycoproteins, protein fragments,
agarose, fibrin, n-butylene, isobutylene, dioxanone, nylons, vinyl
chlorides, amides, ethylenes, n-butyl methacrylate (BMA), metal
matrix composites (MMCs), metal oxides (e.g. aluminum), DETOSU-1,6
HD-t-CDM ortho ester, styrene, and plasma treated surfaces of any
of the above.
[0296] In one preferred embodiment, the bioprotective domain is
formed from a silicone polymer/hydrophobic-hydrophilic polymer
blend. In one embodiment, The hydrophobic-hydrophilic polymer for
use in the blend may be any suitable hydrophobic-hydrophilic
polymer, including but not limited to components such as
polyvinylpyrrolidone (PVP), polyhydroxyethyl methacrylate,
polyvinylalcohol, polyacrylic acid, polyethers such as polyethylene
glycol or polypropylene oxide, and copolymers thereof, including,
for example, di-block, tri-block, alternating, random, comb, star,
dendritic, and graft copolymers (block copolymers are discussed in
U.S. Pat. Nos. 4,803,243 and 4,686,044, which are incorporated
herein by reference). In one embodiment, the
hydrophobic-hydrophilic polymer is a copolymer of poly(ethylene
oxide) (PEO) and poly(propylene oxide) (PPO). Suitable such
polymers include, but are not limited to, PEO-PPO diblock
copolymers, PPO-PEO-PPO triblock copolymers, PEO-PPO-PEO triblock
copolymers, alternating block copolymers of PEO-PPO, random
copolymers of ethylene oxide and propylene oxide, and blends
thereof. In some embodiments, the copolymers may be optionally
substituted with hydroxy substituents. Commercially available
examples of PEO and PPO copolymers include the PLURONIC.RTM. brand
of polymers available from BASF.RTM.. In one embodiment,
PLURONIC.RTM. F-127 is used. Other PLURONIC.RTM. polymers include
PPO-PEO-PPO triblock copolymers (e.g., PLURONIC.RTM. R products).
Other suitable commercial polymers include, but are not limited to,
SYNPERONICS.RTM. products available from UNIQEMA.RTM..
[0297] The silicone polymer for use in the
silicone/hydrophobic-hydrophilic polymer blend may be any suitable
silicone polymer. In some embodiments, the silicone polymer is a
liquid silicone rubber that may be vulcanized using a metal- (e.g.,
platinum), peroxide-, heat-, ultraviolet-, or other
radiation-catalyzed process. In some embodiments, the silicone
polymer is a dimethyl- and methylhydrogen-siloxane copolymer. In
some embodiments, the copolymer has vinyl substituents. In some
embodiments, commercially available silicone polymers may be used.
For example, commercially available silicone polymer precursor
compositions may be used to prepare the blends, such as described
below. In one embodiment, MED-4840 available from NUSIL.RTM.
Technology LLC is used as a precursor to the silicone polymer used
in the blend. MED-4840 consists of a 2-part silicone elastomer
precursor including vinyl-functionalized dimethyl- and
methylhydrogen-siloxane copolymers, amorphous silica, a platinum
catalyst, a crosslinker, and an inhibitor. The two components may
be mixed together and heated to initiate vulcanization, thereby
forming an elastomeric solid material. Other suitable silicone
polymer precursor systems include, but are not limited to, MED-2174
peroxide-cured liquid silicone rubber available from NUSIL.RTM.
Technology LLC, SILASTIC.RTM. MDX4-4210 platinum-cured biomedical
grade elastomer available from DOW CORNING.RTM., and Implant Grade
Liquid Silicone Polymer (durometers 10-50) available from Applied
Silicone Corporation.
[0298] Silicone polymer/hydrophobic-hydrophilic polymer blends are
described in more detail in U.S. patent application Ser. No.
11/404,417, entitled "SILICONE BASED MEMBRANES FOR USE IN
IMPLANTABLE GLUCOSE SENSORS," filed on Apr. 14, 2006, which is
incorporated herein by reference in its entirety.
[0299] It is advantageous that the bioprotective domain have both
high oxygen and aqueous analyte solubility so that sufficient
reactants reach the enzyme layer. Accordingly, in one embodiment,
the concentration of hydrophobic-hydrophilic polymer (e.g.,
PLURONIC.RTM. F-127) relative to silicone polymer (e.g., MED-4840)
is relatively high, e.g., from about 10% to about 30% in the
bioprotective layer 42. In one embodiment, the concentration of
hydrophobic-hydrophilic polymer is from about 15% to about 25%
(e.g., about 20%).
[0300] In preferred embodiments, the thickness of the bioprotective
domain is from about 10 or 15 microns or less to about 125, 150,
175, 200 or 250 microns or more. In more preferred embodiments, the
thickness of the bioprotective domain is from about 20, 25, 30, or
35 microns to about 60, 65, 70, 75, 80, 85, 90, 95, or 100 microns.
In even more preferred embodiments, the bioprotective domain is
from about 20 or 25 microns to about 50, 55, or 60 microns
thick.
Electronics
[0301] The electrodes of the sensing biointerfaces described above
may be electrically coupled at their ends to contacts (or the like)
on the sensor electronics, which are connected to a power source.
In some embodiments, the sensing biointerface and accompanying
electronics are packaged in a complete sensor device that can be
implanted (e.g., transcutaneously or wholly) into a host. In one
embodiment, the sensing biointerface is stretched linearly between
two supports on the complete sensor device. In one embodiment, the
sensing biointerface is coiled or looped to reduce the footprint of
the device. However, whatever configuration of sensing biointerface
is used, it is advantageous to allow both (or numerous) sides of
the biointerface to contact tissue.
[0302] In some embodiments, the biocompatible matrix is
electrically coupled to the sensor electronics and includes a power
source. Namely, the sensor electronics comprise contacts (or the
like) configured to contact the electrodes of the biocompatible
matrix. In one embodiment, a portion of the electrodes of the
biocompatible matrix are exposed at their ends and configured to
engage contacts on the sensor electronics device body. Alternately,
the electrodes are hard-wired into the sensor electronics to
provide electrical coupling. The power source is connected to the
sensor electronics and includes a battery, inductor, or the like,
as is appreciated by one skilled in the art.
[0303] FIG. 15 is a block diagram that illustrates the sensor
electronics in one embodiment. In this embodiment, a potentiostat
134 is shown, which is operably connected to an electrode system
(such as described above) and provides a voltage to the electrodes,
which biases the sensor to enable measurement of an current signal
indicative of the analyte concentration in the host (also referred
to as the analog portion). In some embodiments, the potentiostat
includes a resistor (not shown) that translates the current into
voltage. In some alternative embodiments, a current to frequency
converter is provided that is configured to continuously integrate
the measured current, for example, using a charge counting
device.
[0304] An A/D converter 136 digitizes the analog signal into a
digital signal, also referred to as "counts" for processing.
Accordingly, the resulting raw data stream in counts, also referred
to as raw sensor data, is directly related to the current measured
by the potentiostat 134.
[0305] A processor module 138 includes the central control unit
that controls the processing of the sensor electronics 132. In some
embodiments, the processor module includes a microprocessor,
however a computer system other than a microprocessor can be used
to process data as described herein, for example an ASIC can be
used for some or all of the sensor's central processing. The
processor typically provides semi-permanent storage of data, for
example, storing data such as sensor identifier (ID) and
programming to process data streams (for example, programming for
data smoothing and/or replacement of signal artifacts such as is
described in U.S. Publication No. US-2005-0043598-A1). The
processor additionally can be used for the system's cache memory,
for example for temporarily storing recent sensor data. In some
embodiments, the processor module comprises memory storage
components such as ROM, RAM, dynamic-RAM, static-RAM, non-static
RAM, EEPROM, rewritable ROMs, flash memory, or the like.
[0306] In some embodiments, the processor module comprises a
digital filter, for example, an infinite impulse response (IIR) or
finite impulse response (FIR) filter, configured to smooth the raw
data stream from the A/D converter. Generally, digital filters are
programmed to filter data sampled at a predetermined time interval
(also referred to as a sample rate). In some embodiments, wherein
the potentiostat is configured to measure the analyte at discrete
time intervals, these time intervals determine the sample rate of
the digital filter. In some alternative embodiments, wherein the
potentiostat is configured to continuously measure the analyte, for
example, using a current-to-frequency converter as described above,
the processor module can be programmed to request a digital value
from the A/D converter at a predetermined time interval, also
referred to as the acquisition time. In these alternative
embodiments, the values obtained by the processor are
advantageously averaged over the acquisition time due the
continuity of the current measurement. Accordingly, the acquisition
time determines the sample rate of the digital filter. In preferred
embodiments, the processor module is configured with a programmable
acquisition time, namely, the predetermined time interval for
requesting the digital value from the A/D converter is programmable
by a user within the digital circuitry of the processor module. An
acquisition time of from about 2 seconds to about 512 seconds is
preferred; however any acquisition time can be programmed into the
processor module. A programmable acquisition time is advantageous
in optimizing noise filtration, time lag, and processing/battery
power.
[0307] Preferably, the processor module is configured to build the
data packet for transmission to an outside source, for example, an
RF transmission to a receiver. Generally, the data packet comprises
a plurality of bits that can include a preamble, a unique
identifier identifying the electronics unit, the receiver, or both,
(e.g., sensor ID code), data (e.g., raw data, filtered data, and/or
an integrated value) and/or error detection or correction.
Preferably, the data (transmission) packet has a length of from
about 8 bits to about 128 bits, preferably about 48 bits; however,
larger or smaller packets can be desirable in certain embodiments.
The processor module can be configured to transmit any combination
of raw and/or filtered data. In one exemplary embodiment, the
transmission packet contains a fixed preamble, a unique ID of the
electronics unit, a single five-minute average (e.g., integrated)
sensor data value, and a cyclic redundancy code (CRC).
[0308] In some embodiments, the processor module further comprises
a transmitter portion that determines the transmission interval of
the sensor data to a receiver, or the like. In some embodiments,
the transmitter portion, which determines the interval of
transmission, is configured to be programmable. In one such
embodiment, a coefficient can be chosen (e.g., a number of from
about 1 to about 100, or more), wherein the coefficient is
multiplied by the acquisition time (or sampling rate), such as
described above, to define the transmission interval of the data
packet. Thus, in some embodiments, the transmission interval is
programmable from about 2 seconds to about 850 minutes, more
preferably from about 30 second to about 5 minutes; however, any
transmission interval can be programmable or programmed into the
processor module. However, a variety of alternative systems and
methods for providing a programmable transmission interval can also
be employed. By providing a programmable transmission interval,
data transmission can be customized to meet a variety of design
criteria (e.g., reduced battery consumption, timeliness of
reporting sensor values, etc.)
[0309] Conventional glucose sensors measure current in the nanoAmp
range. In some embodiments, the preferred embodiments are
configured to measure the current flow in the picoAmp range, and in
some embodiments, femtoAmps. Namely, for every unit (mg/dL) of
glucose measured, at least one picoAmp of current is measured.
Preferably, the analog portion of the A/D converter 136 is
configured to continuously measure the current flowing at the
working electrode and to convert the current measurement to digital
values representative of the current. In one embodiment, the
current flow is measured by a charge counting device (e.g., a
capacitor). Preferably, a charge counting device provides a value
(e.g., digital value) representative of the current flow integrated
over time (e.g., integrated value). In some embodiments, the value
is integrated over a few seconds, a few minutes, or longer. In one
exemplary embodiment, the value is integrated over 5 minutes;
however, other integration periods can be chosen. Thus, a signal is
provided, whereby a high sensitivity maximizes the signal received
by a minimal amount of measured hydrogen peroxide (e.g., minimal
glucose requirements without sacrificing accuracy even in low
glucose ranges), reducing the sensitivity to oxygen limitations in
vivo (e.g., in oxygen-dependent glucose sensors).
[0310] In some embodiments, the electronics unit is programmed with
a specific ID, which is programmed (automatically or by the user)
into a receiver to establish a secure wireless communication link
between the electronics unit and the receiver. Preferably, the
transmission packet is Manchester encoded; however, a variety of
known encoding techniques can also be employed.
[0311] A battery 144 is operably connected to the sensor
electronics 132 and provides the power for the sensor. In one
embodiment, the battery is a lithium manganese dioxide battery;
however, any appropriately sized and powered battery can be used
(for example, AAA, nickel-cadmium, zinc-carbon, alkaline, lithium,
nickel-metal hydride, lithium-ion, zinc-air, zinc-mercury oxide,
silver-zinc, and/or hermetically-sealed). In some embodiments, the
battery is rechargeable, and/or a plurality of batteries can be
used to power the system. The sensor can be transcutaneously
powered via an inductive coupling, for example. In some
embodiments, a quartz crystal 96 is operably connected to the
processor 138 and maintains system time for the computer system as
a whole, for example for the programmable acquisition time within
the processor module.
[0312] Optional temperature probe 140 is shown, wherein the
temperature probe is located on the electronics assembly or the
glucose sensor itself. The temperature probe can be used to measure
ambient temperature in the vicinity of the glucose sensor. This
temperature measurement can be used to add temperature compensation
to the calculated glucose value.
[0313] An RF module 148 is operably connected to the processor 138
and transmits the sensor data from the sensor to a receiver within
a wireless transmission 150 via antenna 152. In some embodiments, a
second quartz crystal 154 provides the time base for the RF carrier
frequency used for data transmissions from the RF transceiver. In
some alternative embodiments, however, other mechanisms, such as
optical, infrared radiation (IR), ultrasonic, or the like, can be
used to transmit and/or receive data.
[0314] In the RF telemetry module of the preferred embodiments, the
hardware and software are designed for low power requirements to
increase the longevity of the device (for example, to enable a life
of from about 3 to about 24 months, or more) with maximum RF
transmittance from the in vivo environment to the ex vivo
environment for wholly implantable sensors (for example, a distance
of from about one to ten meters or more). Preferably, a high
frequency carrier signal of from about 402 MHz to about 433 MHz is
employed in order to maintain lower power requirements. In some
embodiments, the RF module employs a one-way RF communication link
to provide a simplified ultra low power data transmission and
receiving scheme. The RF transmission can be OOK or FSK modulated,
preferably with a radiated transmission power (EIRP) fixed at a
single power level of typically less than about 100 microwatts,
preferably less than about 75 microwatts, more preferably less than
about 50 microwatts, and most preferably less than about 25
microwatts.
[0315] Additionally, in wholly implantable devices, the carrier
frequency may be adapted for physiological attenuation levels,
which is accomplished by tuning the RF module in a simulated in
vivo environment to ensure RF functionality after implantation;
accordingly, the preferred glucose sensor can sustain sensor
function for 3 months, 6 months, 12 months, or 24 months or
more.
[0316] The above description of sensor electronics associated with
the electronics unit is applicable to a variety of continuous
analyte sensors, such as non-invasive, minimally invasive, and/or
invasive (e.g., transcutaneous and wholly implantable) sensors. For
example, the sensor electronics and data processing as well as the
receiver electronics and data processing described below can be
incorporated into the wholly implantable glucose sensor disclosed
in U.S. Publication No. US-2005-0245799-A1 and U.S. patent
application Ser. No. 10/885,476 filed Jul. 6, 2004 and entitled,
"SYSTEMS AND METHODS FOR MANUFACTURE OF AN ANALYTE-MEASURING DEVICE
INCLUDING A MEMBRANE SYSTEM."
[0317] Methods and devices that are suitable for use in conjunction
with aspects of the preferred embodiments are disclosed in U.S.
Pat. No. 4,994,167; U.S. Pat. No. 4,757,022; U.S. Pat. No.
6,001,067; U.S. Pat. No. 6,741,877; U.S. Pat. No. 6,702,857; U.S.
Pat. No. 6,558,321; U.S. Pat. No. 6,931,327; and U.S. Pat. No.
6,862,465.
[0318] Methods and devices that are suitable for use in conjunction
with aspects of the preferred embodiments are disclosed in U.S.
Publication No. US-2005-0176136-A1; U.S. Publication No.
US-2005-0251083-A1; U.S. Publication No. US-2005-0143635-A1; U.S.
Publication No. US-2005-0181012-A1; U.S. Publication No.
US-2005-0177036-A1; U.S. Publication No. US-2005-0124873-A1; U.S.
Publication No. US-2005-0051440-A1; U.S. Publication No.
US-2005-0115832-A1; U.S. Publication No. US-2005-0245799-A1; U.S.
Publication No. US-2005-0245795-A1; U.S. Publication No.
US-2005-0242479-A1; U.S. Publication No. US-2005-0182451-A1; U.S.
Publication No. US-2005-0056552-A1; U.S. Publication No.
US-2005-0192557-A1; U.S. Publication No. US-2005-0154271-A1; U.S.
Publication No. US-2004-0199059-A1; U.S. Publication No.
US-2005-0054909-A1; U.S. Publication No. US-2005-0112169-A1; U.S.
Publication No. US-2005-0051427-A1; U.S. Publication No.
US-2003-0032874; U.S. Publication No. US-2005-0103625-A1; U.S.
Publication No. US-2005-0203360-A1; U.S. Publication No.
US-2005-0090607-A1; U.S. Publication No. US-2005-0187720-A1; U.S.
Publication No. US-2005-0161346-A1; U.S. Publication No.
US-2006-0015020-A1; U.S. Publication No. US-2005-0043598-A1; U.S.
Publication No. US-2003-0217966-A1; U.S. Publication No.
US-2005-0033132-A1; U.S. Publication No. US-2005-0031689-A1; U.S.
Publication No. US-2004-0045879-A1; U.S. Publication No.
US-2004-0186362-A1; U.S. Publication No. US-2005-0027463-A1; U.S.
Publication No. US-2005-0027181-A1; U.S. Publication No.
US-2005-0027180-A1; U.S. Publication No. US-2006-0020187-A1; U.S.
Publication No. US-2006-0036142-A1; U.S. Publication No.
US-2006-0020192-A1; U.S. Publication No. US-2006-0036143-A1; U.S.
Publication No. US-2006-0036140-A1; U.S. Publication No.
US-2006-0019327-A1; U.S. Publication No. US-2006-0020186-A1; U.S.
Publication No. US-2006-0020189-A1; U.S. Publication No.
US-2006-0036139-A1; U.S. Publication No. US-2006-0020191-A1; U.S.
Publication No. US-2006-0020188-A1; U.S. Publication No.
US-2006-0036141-A1; U.S. Publication No. US-2006-0020190-A1; U.S.
Publication No. US-2006-0036145-A1; U.S. Publication No.
US-2006-0036144-A1; and U.S. Publication No. US-2006-0016700A1.
[0319] Methods and devices that are suitable for use in conjunction
with aspects of the preferred embodiments are disclosed in U.S.
application Ser. No. 09/447,227 filed Nov. 22, 1999 and entitled
"DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS"; U.S.
application Ser. No. 11/280,672 filed Nov. 16, 2005, and entitled
"TECHNIQUES TO IMPROVE POLYURETHANE MEMBRANES FOR IMPLANTABLE
GLUCOSE SENSORS"; U.S. application Ser. No. 11/280,102 filed Nov.
16, 2005, and entitled "TECHNIQUES TO IMPROVE POLYURETHANE
MEMBRANES FOR IMPLANTABLE GLUCOSE SENSORS"; U.S. application Ser.
No. 11/201,445 filed Aug. 10, 2005 and entitled "SYSTEM AND METHODS
FOR PROCESSING ANALYTE SENSOR DATA"; U.S. application Ser. No.
11/335,879 filed Jan. 18, 2006 and entitled "CELLULOSIC-BASED
INTERFERENCE DOMAIN FOR AN ANALYTE SENSOR"; U.S. application Ser.
No. 11/334,876 filed Jan. 18, 2006 and entitled "TRANSCUTANEOUS
ANALYTE SENSOR"; U.S. application Ser. No. 11/333,837 filed Jan.
17, 2006 and entitled "LOW OXYGEN IN VIVO ANALYTE SENSOR".
[0320] In one embodiment of the present invention, a method is
provided for detecting an analyte, such as glucose, using an
implantable sensing biointerface such as described herein. The
implantable sensing biointerface can be surgically implanted at a
tissue site in a host. Tissue can then be allowed to grow in the
passageways in the matrix of the sensing biointerface. Finally, the
analyte can be detected at a working electrode disposed within the
sensing biointerface matrix, with or without the aid of a membrane
system disposed on the working electrode.
[0321] The term "host" as used herein is a broad term, and is to be
given its ordinary and customary meaning to a person of ordinary
skill in the art (and is not to be limited to a special or
customized meaning), and refers without limitation to a mammal. In
one embodiment, the host is a human.
[0322] The use of the sensing biointerfaces described herein has
several advantages. First, because the biointerface can be
constructed in the form of a thin membrane, it can be implanted
with much less trauma to surrounding tissue. Furthermore, the
thinness of the biointerface can promote rapid in-growth of tissue
and thus, allow the sensor to reach optimal detecting condition
faster. The fact that tissue in-growth can occur from both sides of
the biointerface also promotes fast start-up and an improvement in
the quality of detection. The small scale of the passageways within
the biointerface allows tissue, including vasculature, to grow
closer to the electrodes than would otherwise be possible. Thus the
time lag between a change in analyte levels in the blood stream and
detection of those levels is decreased because the transport
distance of the analyte from blood vessels to the electrodes is
shorter.
[0323] The term "substantially" as used herein is a broad term, and
is to be given its ordinary and customary meaning to a person of
ordinary skill in the art (and is not to be limited to a special or
customized meaning), and refers without limitation to being largely
but not necessarily wholly that which is specified.
[0324] All references cited herein, including but not limited to
published and unpublished applications, patents, and literature
references, are incorporated herein by reference in their entirety
and are hereby made a part of this specification. To the extent
publications and patents or patent applications incorporated by
reference contradict the disclosure contained in the specification,
the specification is intended to supersede and/or take precedence
over any such contradictory material.
[0325] The term "comprising" as used herein is synonymous with
"including," "containing," or "characterized by," and is inclusive
or open-ended and does not exclude additional, unrecited elements
or method steps.
[0326] All numbers expressing quantities of ingredients, reaction
conditions, and so forth used in the specification are to be
understood as being modified in all instances by the term "about."
Accordingly, unless indicated to the contrary, the numerical
parameters set forth herein are approximations that may vary
depending upon the desired properties sought to be obtained. At the
very least, and not as an attempt to limit the application of the
doctrine of equivalents to the scope of any claims in any
application claiming priority to the present application, each
numerical parameter should be construed in light of the number of
significant digits and ordinary rounding approaches.
[0327] The above description discloses several methods and
materials of the present invention. This invention is susceptible
to modifications in the methods and materials, as well as
alterations in the fabrication methods and equipment. Such
modifications will become apparent to those skilled in the art from
a consideration of this disclosure or practice of the invention
disclosed herein. Consequently, it is not intended that this
invention be limited to the specific embodiments disclosed herein,
but that it cover all modifications and alternatives coming within
the true scope and spirit of the invention.
* * * * *